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SUMMARY 
Chronic Venous Insufficiency (CVI) is characterized by chronic venous hypertension 
from blood pooling in the lower limbs. The resulting symptoms include leg pain, varicose veins, 
fatigue, venous edema, skin pigmentation, inflammation, induration, and ulceration. Reflux from 
incompetent venous valves is a factor in up to 94% of individuals with CVI. Current treatments 
of CVI include compression stockings, drug therapy, vein disabling, venous stenting, and 
surgical correction with varying rates of success. However, a minimally invasive correction of 
deep venous reflux does not currently exist. A transcatheter prosthetic venous valve has the 
potential to be an effective, minimally invasive treatment for deep venous reflux which could 
treat up to 1.4 million individuals in the United States suffering from venous ulceration and make 
more than 1.7 billion dollars each year. Previously developed prosthetic venous valves have had 
problems with competency, patency, thrombogenicity, biocompatibility, and incorrect sizing. To 
meet the clinical need a prosthetic valve needs to be developed which succeeds where previous 
valves have failed.  
This thesis describes the design, analysis, pre-clinical testing, and evaluation of a novel 
prosthetic venous valve. Design specifications for an effective prosthetic venous valve were 
created. Verification tests were developed and performed which demonstrated that the valve met 
every design specification. Finite element and computational fluid dynamics simulations were 
performed to analyze the valve and calculated a maximum shear rate of 2300 s
-1
 in the valve 
during the high forward flow after a Valsalva maneuver. The valve is made of a biocompatible 
material that has low thrombogenicity, Poly(vinyl-alcohol) cryogel. On the average, the valve 
allows less than 0.5 mL/min of reflux at low and high retrograde pressures even after 500,000 
  xxi   
 
cycles, indicating that it will reduce the reflux of individuals with venous reflux by more than 
99.4%. The valve closes in less than 0.07 seconds and allows the distal pressure to rise to an 
average of 7% of the equilibrium pressure 30 seconds after a simulated ankle flexion. The valve 
increases the outflow resistance an average of 2.3 mmHg*min/L which is much less than 
obstruction levels,  5 mmHg*min/L. The valve can fit in a 16 French catheter and is capable of 
percutaneous delivery. The base of the valve is 1.5 times the diameter of the vein in which it is to 
be implanted to help correct orientation upon deployment. Fluid behind the valve’s leaflets is 
ejected with a forward flow rate of 400 mL/min, suggesting that thrombus formation will not 
occur at this location. A stented valve remained patent in a porcine blood flow loop for 3 hours. 
The valve remains competent without buckling in a constricted vein at rest. The valve can 
expand to fit a vein with a maximum diameter 1.4 times the valve's initial diameter with low risk 
of tearing or leaflet prolapse.  
An IACUC protocol for a 12 week study to test the valve in sheep was prepared and 
approved. A study to evaluate the valve in humans is proposed with endpoints that can be tested 
for statistical significance and compared with other treatments for CVI. A set of valves which 
will correct reflux in the majority of common femoral, femoral, and popliteal deep veins is 
proposed and a sizing guide for surgeons is provided. The minimum distance between prosthetic 
valves placed in the same vein segment is 13 cm.   
A comparison of this valve with previously developed prosthetic venous valves and 
recommendations for work to be performed in the future are given. The valve proposed in this 
work is the only valve to meet all design specification for an effective prosthetic venous valve, 
and therefore shows great potential to be a minimally invasive treatment for deep venous reflux.    
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CHAPTER 1: INTRODUCTION 
Chronic Venous Insufficiency 
Chronic Venous Insufficiency (CVI) is characterized by chronic venous hypertension 
from blood pooling in the lower limbs [1, 2]. In healthy veins, muscle contractions efficiently 
pump blood back to the heart while venous valves close to prevent reflux (see Figure 1) [3]. 
Venous hypertension and CVI can develop in the presence of venous reflux, venous obstruction, 
and calf muscle pump dysfunction (see Figure 1) [1]. The resulting symptoms include leg pain, 
varicose veins, fatigue, venous edema, skin pigmentation, inflammation, induration, and 
ulceration [4].  
Prevalence and Economic impact 
The risk of developing CVI increases with age, body mass index, height, family history 
of CVI, European ancestry, Hispanic ethnicity, pregnancy, prolonged standing, straining during 
bowel movements, being female, and residing in an industrialized country [5-10].  
Studies on the prevalence of varicose veins have varied from 2-57% and < 1-73% for 
men and women respectively depending on the ancestry and degree of industrialization of the 
population studied as well as the disease criteria of the individual study [9]. These studies have 
also reported < 1-4.7% and < 1-5.5% of men and women respectively have a history of venous 
ulceration [9]. In the United States More than 7 million individuals have CVI with an estimated 
2.5 million having venous ulcers [11, 12]. The United States spends up to 3 billion dollars 
annually treating venous ulcers [13].  It is estimated that every year 1.5-2% of the total health 
care budget for the United Kingdom, France, and West Germany is spent on treating venous 
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disease [14]. One study reported the onset of chronic leg ulceration to occur by age 40 for 24%, 
age 50 for 39%, and age 60 for 58% of individuals [15]. With the life expectancy in the United 
States being approximately 80 years, individuals with CVI may require treatment for 20-40 
years, resulting in large lifetime cost of treatment per patient [16]. 
  
Figure 1: In healthy veins, muscle contractions efficiently pump blood back to the heart while venous valves 
close to prevent reflux (left). Factors which lead to the development of CVI include incompetent venous valves 
which allow reflux, outflow obstruction which increases outflow resistance, and calf muscle pump dysfunction 
(right).  
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There are additional indirect costs not included in the previous estimates. For instance, 
each year, an estimated 2 million work days are lost in the United States because of leg 
ulceration [11]. One study reported that 21% of working age individuals with chronic leg 
ulceration were severely limited or unable to work [17]. 
Quality of Life 
In addition to the economic impact, the quality of life of individuals with CVI is 
decreased. Beyond concerns with the symptoms of CVI, patients also report having concerns 
with mobility, odor, cosmetic appearance, social embarrassment, and depression [11, 14]. 
Treatment of chronic ulcers has been correlated with a reduction in anxiety, depression, hostility, 
and cognitive impairment in patients [14].  
Main Contributors to Venous Hypertension 
The three main contributors to the chronic venous hypertension which results in CVI are 
venous reflux, venous obstruction, and calf muscle pump dysfunction (see Figure 1) [1]. Venous 
hypertension can be quantified by measuring a patient’s ambulatory venous pressure (AVP), 
which is the mean pressure in the foot or lower leg during exercise [1]. There is a strong 
correlation between higher AVP measurements and ulceration (see Figure 2) [1, 18].  
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Figure 2: Relationship between ambulatory venous pressure and the incidence of ulceration (image from 
[18]). 
Venous Reflux 
Three venous systems of concern with CVI are the deep, superficial, and perforating 
veins. The deep venous system is composed of large diameter veins deep inside the leg, these 
include the iliac, common femoral (CFV), femoral, and popliteal veins (see Figure 3). The 
superficial venous system is composed of smaller diameter veins located in the leg closer to the 
skin, these include the great saphenous and small saphenous veins (see Figure 4). Perforating 
veins connect the deep and superficial veins throughout the calf and thigh (see Figure 4). Venous 
valves are located in each of these systems which allow unidirectional flow back to the heart (see 
Figure 5). These valves are naturally open and do not significantly impede forward flow to the 
heart (see Figure 6) [19, 20]. The leaflets of normal valves come together in response to 
retrograde pressure to close the vein and prevent reflux (see Figure 7 and Figure 8) [21-23]. 
Venous reflux occurs when valves become incompetent and allow retrograde flow. 
Primary valvular incompetence results from age related structural changes in the valve, such as 
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thinning of the leaflets. Secondary incompetence occurs when valves are damaged after deep 
vein thrombosis (DVT) and recanalization (restoration of the vein's lumen).  
Venous reflux is present in 77-97% of symptomatic limbs, suggesting it is a major 
contributor to CVI [24-29]. The symptom severity of individuals with CVI is related to the total 
amount of reflux and the location of the refluxing vein segments.  
Reflux is commonly quantified by measuring the reflux duration or a patient’s venous 
filling index (VFI). Healthy native venous valves typically close in less than 0.5 seconds under 
retrograde pressure [30, 31]. While increased valve closure time is not highly correlated with 
increased symptom severity, it is common clinical practice to deem a valve incompetent if it 
takes more than 0.5 seconds to close [31-34]. The median valve closure time for an individual 
with CVI is 3.6 seconds [32]. VFI is the average filling rate of all the veins in the calf when an 
individual changes from the supine to the standing position and is measured using 
plethysmography (PG) and is the combined measurement of arterial inflow and venous reflux. A 
normal VFI is less than 2 mL/s, with higher measurements correlated with increased symptom 
severity [1, 35-39]. This suggests that the total amount of reflux is indicative of the symptom 
severity of a patient. Individuals with incompetent popliteal veins typically have a VFI greater 
than 5 mL/s, with skin changes and ulceration occurring with a VFI greater than 10 mL/s [35]. 
The location of refluxing vein segments also plays a significant role in the symptom 
severity of a patient. The risk of skin changes and ulceration for individuals with reflux in the 
deep venous system is higher than in those with superficial or perforator reflux [27, 33, 36, 40]. 
Approximately 43-74% of individuals with CVI and 49-88% with ulceration have deep venous 
reflux [25, 40-44]. The risk of skin changes an ulceration also increases when reflux is present in 
more than one venous system [25, 33, 40, 42].  
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Correction of deep venous reflux often leads to a drastic reduction of symptoms, with one 
study reporting a 78% ulcer healing rate when refluxing valves were surgically corrected and 
remained competent [45]. 
 
Figure 3: Veins in the Deep Venous System (image from [46]). 
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Figure 4: Veins in the superficial and perforating venous systems (image from [46]). 
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Figure 5: Normal venous flow paths with unidirectional venous valves. Blood flows from the feet (b) towards 
the heart (a). Perforating veins (f) connect superficial and deep venous systems (image from [9]). 
 
 
Figure 6: Proximal (left) and distal (right) views of an open saphenous venous valve (image from [19]). 
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Figure 7: Ultrasound images of a venous valve in the great saphenous vein at the ankle. Distal (a, b) and side 
(c, d)views of valve leaflets when open (left) and closed (right) (image from [47]). 
 
 
Figure 8: View of a closed venous valve (image from [19]). 
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Outflow Obstruction 
Venous outflow obstruction makes it difficult for blood to leave the lower limbs, thus 
contributing to the development of venous hypertension and CVI (see Figure 1). Obstruction is 
typically caused by DVT when there is insufficient recanalization [1, 48]. Other causes of the 
obstruction can be from extramural venous compression, congenital agenesis, or hypoplasia of 
the vein [1].Venous obstruction is present in 14-42% of symptomatic limbs [26, 28, 29]. Patients 
with venous reflux and outflow obstruction typically have a greater AVP and higher rates of 
ulceration than individuals with only one factor present [18, 27].  
Calf Muscle Pump Dysfunction 
In healthy legs, the calf muscle pump ejects blood out of the lower limbs which helps to 
prevent the development of venous hypertension [3]. A reduction in the efficiency of the calf 
muscle pump to eject blood out of the limb will also contribute to the development of venous 
hypertension and CVI [29, 36, 49]. While the efficiency of the calf muscle pump is decreased by 
outflow obstruction and venous reflux, calf muscle pump dysfunction, such as a reduction in 
pump compliance, will also reduce the efficiency [29, 36, 49, 50]. The efficiency of the calf 
muscle pump can be quantified by measuring the fraction of blood ejected (EF) during a single 
contraction using PG [29, 36, 49]. Lower EF measurements have been correlated with higher 
AVP measurements and incidents of ulceration with symptomatic limbs having an EF less than 
60% [29, 36, 38, 39, 49, 50]. Approximately 44% of limbs with CVI have reduced calf muscle 
pump compliance [29]. 
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Quantifying Symptom Severity 
The Clinical-Etiology-Anatomy-Pathophysiology (CEAP) system is commonly used to 
classify patients according to symptoms (see Figure 9) [51]. This classification system attempts 
to capture the progression of CVI symptoms from low to high severity: telangiectases, varicose 
veins, edema, skin changes, and ulceration (see Table 1). However, CEAP was not designed to 
measure improvements in a patient’s symptoms in response to treatment and is a relatively static 
measurement [2, 52, 53].  
The Venous Clinical Severity Scoring System (VCS) is a tool available to measure the 
symptom severity of individuals with CVI [4, 54, 55]. The VCS rates pain, varicose veins, 
venous edema, skin pigmentation, inflammation, induration, active ulcer number, active ulcer 
duration, active ulcer size, and use of compression therapy for each subject on an objective scale 
from 0 to 3, with a maximum score of 30 (see Figure 10) [4, 54]. A strong correlation exists 
between CEAP class and VSC score (seeTable 2) [55, 56]. The VCS score has been used in 
several studies to evaluate the response of a patient’s symptoms for a given treatment [52, 53, 
57-66]. Patient VCS scores have been shown to change in response to treatment within 3 days, 
suggesting that this score quickly captures changes in symptoms [52].  
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Figure 9: CEAP classification system (image from [51]). 
 









    
 
 
Figure 10: Revised Venous Clinical Severity Score (image from [4]). 
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Table 2: Relationship between CEAP class and VCS score (combined data from [55] and [56]). 
CEAP Class 95% Confidence Interval 







Approaches to Treatment 
Treatments for CVI include exercise, compression, medication, vein disabling, venous 
stenting, surgical correction, and valve replacement. Thus far these treatments have demonstrated 
varying levels of efficacy in reducing the symptom severity. In practice the most conservative 
treatment is applied first, typically compression stockings, with more invasive procedures being 
pursued when symptoms do not significantly improve [67]. The appropriateness of each 
treatment is further determined by the functionality of the calf muscle pump as well as the 
presence and location of venous reflux and obstruction (see Figure 11) [68].  
The time spent by an individual caring for an ulcer has been found to be highly correlated 
with feelings of resentment and anger [11]. Therefore, in addition to symptom relief, the time 
required of an individual for a given treatment must be considered when evaluating its efficacy. 
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Figure 11: A simplified overview for the diagnosis and treatment of CVI (image from [68]). 
Exercise 
Exercise has been proposed as a treatment to improve calf muscle pump function [65]. 
Padberg performed a randomized study of 28 individuals with CEAP classifications C4-6, with 
15 individuals undergoing an exercise regimen to strengthen their calf muscles [65]. After 6 
months the mean EF in the experimental group increased by 12% and was statistically significant 
compared to the control group. The mean VCS score decreased from 9.4 to 8.7 for the 
experimental group, which was not statistically significant. VFI increased by 5% for the control 
group, which was not statistically significant.  
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Compression 
Compression of the symptomatic limb using elastic stockings is the most common 
treatment for CVI. Elastic stockings may provide uniform or graduated compression to a limb 
with pressures ranging from 15 to 60 mmHg, varying from ankle to thigh length [67, 69]. 
Stockings may vary from ankle to thigh length [69]. Compression of the limb reduces the cross-
sectional area of the veins which promotes coaptation of venous valve leaflets which reduces 
venous reflux [70]. Additionally, reduction of the cross-sectional area of the vein increases the 
flow velocity and discourages the formation of outflow obstructions from stagnant blood [70]. 
Reduction of the cross-sectional area of the veins also promotes coaptation of venous valve 
leaflets which reduces venous reflux [70]. 
The use of compressive stockings has been shown to moderately improve AVP, VFI, and 
EF for individuals with both superficial and deep venous reflux (see Table 3) [38]. Cesarone 
reported that the average VCS score in 31 individuals with CVI decreased from 8.4 to 5.7 after 
eight weeks when treated with compression therapy, which corresponds to a mild reduction in 
symptom severity [61].   
Approximately 50% of patients are unable to wear compression stockings because of 
physical limitations, such as frailty or obesity, or simultaneous arterial insufficiency [71]. Even 
in the presence of severe symptoms, individuals who can wear compressive stockings have a 
noncompliance rate up to 68% [72, 73]. Patients have questioned the benefits of wearing 
compressive stockings and expressed concerns that they are uncomfortable to wear [72, 74]. 
Other patients have reported that the appropriate type of compressive stockings could not be 
acquired because of high cost and inadequate insurance reimbursement [75].  
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Table 3: Mean percent change in hemodynamic parameters from elastic compression use; all values are 
statistically significant (p < 0.01) (recreated from [38]). 
 Mean Percent Change 
 Limbs with superficial venous 
incompetence (n = 22)  
Limbs with deep venous 
incompetence (n = 22) 
Ambulatory Venous Pressure -48 -18 
Venous Filling Index -25 -28 
Ejection Fraction 19 49 
Medication 
Several pharmacological agents have been tested in clinical trials to treat individuals with 
CVI [68, 76-78]. Venoactive medications are intended to increase venous tone and capillary 
permeability and have shown to reduce pain, edema, itching, heaviness, swelling, and cramping, 
trophic skin changes, active ulceration [77-79].  
However, few studies have measured the change in a subject’s VCS score in response to 
medication. Cesarone reported that the average VCS score in 31 individuals with CVI decreased 
from 8.4 to 5.7 after eight weeks when treated with the pharmacological agent Pycnogenol® 
alone, and to 4.0 when combined with compression therapy [61].   
Vein Disabling 
Various methods, many being minimally invasive, have been used to disable problematic 
veins in the superficial and perforator venous systems and compel blood to use an alternate route 
to the heart. These methods include ligation, radiofrequency ablation, endovenous laser ablation, 
sclerotherapy, SEPS, PAPS, and Cyanoacrylate (super glue) [67, 68, 79, 80]. The baseline and 
mean VCS scores for several vein disabling procedures are shown in Table 4  
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Table 4. Complications include bruising, pigmentation, nerve injury, infection, and deep 
venous thrombosis, and occur in 5-20% of subjects [66, 67, 79, 81]. The long term efficacy of 
these procedures is mixed, as 7-71% of varicose veins return after a vein disabling procedure due 
to the recurrence of reflux [81-86]. 
Table 4: Baseline and follow-up mean VCS scores for various vein disabling procedures. 
 Mean VCS Score  
Procedure Baseline Last follow-up Time of last follow-up 
Venous Stripping [57]  10.1 1.45 ~ 16 months 
Radiofrequency Ablation [52] 8.8 2.7 6 months 
Sclerotherapy [58] 8 2 ~ 20 months 
Laser ablation [59] 4 0 12 weeks 
Venous Stenting 
Venous stenting has been used to treat outflow obstruction in deep veins [87-92]. One 
study of venous stenting of 982 patients reported that after 5 years, 62% of limbs were free of 
pain, 32% had no swelling, and 52% had their ulcers heal [89]. Another study reported the mean 
patient VCS score decreasing from 8.5 to 2 after approximately 27 months [63]. However, 
venous stenting alone has not demonstrated a statistically significant improvement in AVP, EF, 
and VFI [89-92].   
Surgical Correction 
Surgical correction of deep venous incompetence includes valvuloplasty, banding, 
femoral transposition, valve transplantation, and neovalve construction [93]. Valvulplasty is the 
surgical repair of an existing incompetent venous valve and has an ulcer recurrence rate of 21-
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50% and a competency rate of 42-91% [93]. Banding is a technique which promotes valve 
competence by placing a sleeve or cuff around a vein to reduce its diameter and has an ulcer 
recurrence rate of 20-27% and a competency rate of 70-100% [93]. Femoral transposition is the 
surgical connection of an incompetent femoral vein to another vein which is competent (see 
Figure 12). Femoral transposition has an ulcer recurrence rate of 25-56% and a competency rate 
of 40-77% [93]. Transplantation is the surgical insertion of a vein segment with a competent 
valve and has an ulcer recurrence rate of 6-67% and a competency rate of 25-90% [93]. 
However, up to 40% of valves become incompetent after being transplanted [94]. Cryopreserved 
valves have been explored as an option for surgical transplantation with poor results [95, 96]. In 
one study, 74% of valves were incompetent after thawing, only 27% of valves implanted into 
human subjects were still competent and patent after 2 years, and ulcer recurrence was 50% after 
3 years [95]. Neovalve construction is accomplished by manipulating the native venous tissue to 
create a leaflet and has an ulcer recurrence rate of 0-17% and a competency rate of 68-100% 
[93].  
Each of the aforementioned surgical procedures is highly invasive and requires an open 
surgery. Additionally, transposition and transplantation procedures are not always possible for 
patients with adverse anatomy or for which a suitable donor valve cannot be found [43, 97-99]. 










Figure 12: Before (left) and after (right) the transposition of an incompetent femoral vein into a competent 
great saphenous vein (image from [93]). 
 
Prosthetic Venous Valves 
A prosthetic venous valve has the potential to correct reflux in the deep, superficial, and 
perforating venous systems. While alternative minimally invasive treatments have the potential 
to stop reflux in the superficial and perforating venous systems, currently only invasive 
treatments exist for the correction of deep venous reflux. As deep venous incompetence is 
present in approximately 49-88% of individuals with venous ulcers, a minimally invasive 
treatment for deep venous reflux could treat up to 2.2 million of the 2.5 million individuals in the 
United States suffering from venous ulceration [11, 25, 40, 42, 43]. With up to 3 billion dollars 
spent annually in the United States to treat venous ulcers, the potential market for a minimally 
invasive treatment of deep venous reflux could be more than 2.6 billion dollars [25].  
Dotter was the first to suggest the concept of a transcatheter venous valve [101]. Such a 
valve would meet the need for a minimally invasive treatment for deep venous reflux. Three 
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types of replacement valves have been developed by various researchers: mechanical, 
bioprosthetic, and polymer.  
Mechanical 
Taheri et al. developed a bicuspid valve made of platinum or pyrolyte carbon-covered 
titanium (see Figure 13) [12, 102-104]. The valves had inner diameters of 5-10mm. Under a 
pressure head of 100 mmHg the valve had 145 mL/min of reflux and a forward flow rate of 300 
mL/min. The outflow resistance of the valve and the system was 333 mmHg*min/L. After 5 
months of fatigue testing one valve incurred a small crack which was suspected to have occurred 
during manufacturing. Ten valves were implanted into nine dogs via transverse venotomies. Two 
dogs were sacrificed after 3 months because of valve migration and displacement. The remaining 
7 dogs were sacrificed after two years. One valve was still patent but all were rendered 
functionless by neointimal hyperplasia. 
 
 
Figure 13: Taheri valve (image from[12]). 
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Bioprosthetic 
McLachlin harvested vein segments containing valves from dogs [105]. 30 segments 
were implanted into the dogs they were harvested from, with 24 being patent and 16 remaining 
competent at 4 weeks. 14 segments were implanted into dogs that were different from the 
donors, with 1 remaining patent and none being competent at 4 weeks.   
Gerlock created bioprosthetic venous valves using cardiac valves and implanted them 
into the inferior vena cavas of four dogs [106]. Two valves were checked in two dogs and found 
to be patent at 6 months. The remaining valves were checked at 8 months and found to be patent.  
Hill created a bicuspid valve design by placing glutaraldehyde-fixed human umbilical 
cord segments over a bicuspid shaped aluminum rod (see Figure 14) [107]. Ten umbilical valves 
were surgically implanted into dogs. Valves were supported in place by quarter inch stainless 
steel cylinders which were surrounded by the vein to prevent blood contact. All valves occluded 
by 8 days. When the valves were harvested and examined red clot was prominent.  
 
 
Figure 14: Umbilical valve created by Hill (image from Hill 1985 [107]). 
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Dalsing transplanted a jugular vein valve incorporating a 6-8mm diameter Z-stent into 5 
dogs using a 16 French sheath [108]. Barbs were used to prevent valve migration for some 
valves. One valve was patent when the dogs were sacrificed at 1-4 weeks. One valve without 
barbs migrated to the lung. Barbs were observed to cause heavy scarring. Clotting was observed 
inside the valves and at the distal and proximal ends where the stent interfaced with the vein. The 
valve that remained patent did not have barbs, was slightly oversized for the vein, and "was 
placed in a relatively high-flow system” [108]. 
Ofenloch harvested external jugular vein segments containing valves from goats and 
sutured them to 10mm Wallstents (see Figure 15) [94]. These valves were then transplanted into 
the opposing external jugular veins of the goats used for the initial harvest using a 12 French 
catheter. Five goats were sacrificed after 1 week and all valves were patent and competent. 
Thrombus had formed on the stent on the downstream end for all valves. At 6 weeks six goats 
were sacrificed and all valves were patent while 5 were competent. Recanalization had 
obliterated the incompetent valve.  
 
 
Figure 15: Replacement valve made by Ofenloch (image from [94]). 
 
Gomez-Jorge sutured a portion of a gluteraldehyde-fixed bovine external jugular-vein 
containing a native valve to self-expanding nitinol Symphony stents, 8.9-14mm in diameter (see 
Figure 16) [109]. Eleven of these valves were deployed into 11 pigs using 12-24 French 
catheters.  Of seven acute procedures, five valves were competent at implantation. Of the four 
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survival procedures, one pig died by one week, presumed to be from exsanguination, and had its 
leaflets entrapped by postmortem thrombus. The other three were sacrificed at 1-2 weeks and 
had valves that were still patent and competent. All four valves had pronounced inflammatory 
foreign body reactions.  
 
 
Figure 16: Replacement valve made by Gomez-Jorge (image from [110]). 
 
Thorpe, et al, fabricated a bicuspid vein valve by combining porcine small intestinal 
submucosa to a Z-stent. Valves were delivered into pigs using a 16-Fr catheter and demonstrated 
short term patency [111].  
Hasaniya constructed replacement venous valves from bovine external jugular vein 
segments containing valves [112]. Ten valves were tested in-vitro, with eight being considered to 
be competent up to 260 mmHg. 
Pavcnik developed three incremental stented valve designs, BVV1 (see Figure 17), 
BVV2 (see Figure 18), and BVV3 (see Figure 19), with leaflets made from SIS, a biomaterial 
derived from the submucosal layer of the porcine small intestine [110, 113-120]. The SIS leaflets 
are intended to act as temporary scaffolding for host cells to ultimately cover and replace the 
SIS. An 11 French catheter was used to deliver 25 BVV1 valves into 12 sheep with 4/5 being 
patent at 1 month, 10/10 patent at 3 months, and 10/10 patent at 6 months. The valve that 
occluded was tilted during implantation. Tilting was a factor in decreasing the function of three 
valves, with one these valves developing thrombus and occluding. The leaflets thickened at the 
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base and increased in rigidity resulting in moderate reflux at 3 months. An inflammatory 
response was observed around the valve. The BVV1 was implanted into 3 human subjects. At 1 
year, all valves were still patent with 2 valves being competent. Symptoms improved in the two 
subjects in which the valves remained competent. 
The BVV2 valve design modified the stent geometry of the BVV1 to reduce the risk of 
misalignment [117, 120]. A 10 French sheath was used to implant 48 valves into the jugular 
veins of 14 sheep. After 6 weeks all valves were patent and 44 were competent. All valves were 
free of thrombus.  
The BVV3 valve was designed to bring the leaflets closer together and prevent them from 
contacting the vein wall and to increase the size of the sinus region [110, 118, 119]. A 10 French 
catheter was used to deliver 12 of these valves into the jugular veins of 6 sheep. All valves were 
patent and one valve was incompetent at 5 weeks. BVV3 valves were implanted into 15 patients 
with a 12 French catheter. One valve was incompetent at implantation. Four valves occluded, 3 
in less than 2 weeks and one at 7 months. At 3 months only 2 valves remained competent. At 12 
months none of the valves had migrated and none were competent.  
 
 
Figure 17: BVV1 (image from [110]). 




Figure 18: BVV2 before (left) and after (right) implantation cellularization (images from [117]). 
 
  
Figure 19: BVV3 before (left) and after (right) implantation and cellularization (images from [110]). 
 
Pavcnik also created a percutaneous autogenous venous valve (PAVV) by suturing native 
sheep valves to 13-15mm diameter stents (see Figure 20) [121]. Nine valves were implanted into 
9 sheep using a 13-Fr catheter and were secured by barbs. The PAVV leaflets were oriented in 
the same direction as the sheep's native valve. One valve was damaged during insertion and was 
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rendered incompetent. After 3 months the remaining 8 valves were incorporated into the vein 
wall, competent, and free of thrombus. Chronic inflammation and foreign body type giant cells 
were present around sutures and stent wires near the vein wall. 
 
 
Figure 20: PAVV valve developed by Pavcnik (image from [121]). 
 
Venpro developed the PVVB valve, a gluteraldehyde preserved bovine external jugular-
vein segment containing a native valve sutured to nitinol Symphony stents, 10-14mm in diameter 
(see Figure 21) [122-126]. In vitro testing found valve reflux under a 287 mmHg pressure head 
to be 120 mL/min in valves made from fresh specimens and 40 L/min in fixed tissue valves. The 
pressure drop across the valve was 2.9 mmHg with a flow rate of 1200 mL/min, resulting in a 
combined resistance of the flow system and the valve of 322 mmHg*min/L. Valves were 
constrained in place by oversizing the diameter by 2mm. 18 valves were deployed into 10 pigs 
using a 16 French catheter. All valves were deemed patent and competent after insertion. 5 pigs 
received vitamin K for anticoagulation, developed bleeding complications and were sacrificed at 
2 weeks; of the 8 valves implanted in this group, 7 were patent and 3 were competent. 5 pigs 
received aspirin for anticoagulation and were sacrificed at 4 weeks; of the 10 valves implanted in 
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this group, 5 were patent, 3 were competent, and 5 valves experienced thrombosis. One valve 
migrated and was suspected to have been undersized. A fibrous layer between the stent and vein 
and a fibrous capsule around the stent developed for all valves. Some stents were found to have 
not fully expanded. The PVVB was also implanted into 5 human subjects. One valve remained 
patent and competent at 16 months, the remaining four valves occluded. One valve migrated into 
the pulmonary artery. Ultimately this valve was deemed unfit for further use in venous 
implantation [110].   
 
 
Figure 21: PVVB developed by Venpro (image from [125]). 
 
Kucher encased 8mm Symphony stents inside external jugular vein segments containing 
valves harvested from dogs and compared their performance to end-to-end anastomosis grafts in 
seven dogs [127]. Seven valves were delivered using 11 French catheters and expanded a little 
larger than the vein diameter to prevent migration. One dog had both grafts occlude in less than 2 
weeks after surgery while the remaining valves and grafts were still patent after 120 days. 
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Minimal to moderate stenosis was present at the suture lines which raised concerns that 
thrombosis may be caused from the sutures themselves.  
Teebken fabricated 12 tissue engineered venous valve grafts by repopulating 
decellularised allogeneic ovine veins with the future recipient’s myofibroblasts and endothelial 
cells [128, 129]. The burst strength of these valves was an average of 2085 mmHg. These grafts 
were implanted into the external jugular veins of 12 sheep. Anticoagulants were not dispersed 
after surgery. Valves with reflux lasting more than 1.5 seconds were deemed incompetent. Four 
sheep were sacrificed at 1 week and all valves were patent and competent; thrombus had formed 
at the suture site and in the sinus in two valves. Four sheep were sacrificed at 6 weeks and all 
valves were patent and competent; thrombus had formed at the suture site and in the sinus in all 
four valves. The remaining four valves were harvested at 12 weeks where 3 were patent and 2 
were competent. A control group of 8 sheep with implanted autografts was also studied. These 
grafts remained patent and competent for the 6 weeks they were studied.  
Wei combined endothelial progenitor cells (EPC) with allogenic deculluarized valved 
venous stents and implanted 12 of these valves into 12 dogs [130]. A control group of 12 dogs 
which had autogenous valves implanted was also studied. The EPC valves had a reflux velocity 
of 1.4 ± 0.3 cm/s while the autogenous valves had no reflux. The maximum forward flow 
velocity was 18.2 ± 3.3 cm/s for the EPC valves and 21.3 ± 2.1 cm/s for the autogenous valves. 
After valve closure the sinus region expanded from 7.1 to 8.4 mm (116.8%) for the EPC valves 
and from 7.0 to 8.2mm (118.5%) for the autogenous valves. 
Dijkstra endovenously transferred a stented venous valve into the internal jugular veins of 
16 sheep (see Figure 22) [131]. Thrombosis, tilting, endoleak, or migration of valves was not 
observed in any of the sheep after six months. Six valves have been implanted into four human 
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subjects with leg ulcers. After insertion, 2 ulcers healed, 1 increased in severity, and 1 remained 
the same. One of these valves had a type 1 venous endoleak.  
 
 
Figure 22: Stented valve made by Dijkstra (image from [131]). 
 
Liu created a porous tissue engineered a vein valve by seeding scaffolds made of 
Poly(lactic-co-glycolic acid) (PLGA) with cells (see Figure 23). The scaffold had an inner 
diameter of 9mm and a wall thickness of 0.9 mm. Valves were studied in vitro using PBS as the 
working fluid. The valves had an opening pressure of 3.8 ± 0.7 mmHg. Reflux rates for the 
valves decreased from approximately 16 to 12 mL/min as the pressure head increased from 100 
mmHg to 200 mmHg (see Figure 24).  
 
 
Figure 23: Tissue engineered vein containing valve scaffolds made by Liu (image from [132]). 
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Figure 24: Reflux flow rate of tissue engineered venous valve developed by Liu at various pressures. The 
virtical axis is reflux (mL/min) and the horizontal axis is pressure (mmHg) (image from [132]). 
 
Wen fabricated tissue engineered vein valves using two types of bone marrow derived 
progenitor cells obtained from canine multipotent adult progenitor cells (MAPC) and endothelial 
progenitor cells (EPC) (see Figure 25) [133]. 
 
 
Figure 25: Tissue engineered vein containing venous valve made by Wen (image from [133]). 
 
Polymer 
Hill created a bicuspid valve by dip coating a mandrel in liquid Pellethane and cutting 
open the orifice (see Figure 26) [107]. This valve had an opening pressure of 4.5mmHg. After 47 
days of fatigue-cycles at 120/80 mmHg pressures at 60 bpm the valve showed no signs of 
material weakening. Ten Pellethane valves were surgically implanted into dogs. Valves were 
supported in place by quarter inch stainless steel cylinders which were surrounded by the vein to 
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prevent blood contact. All valves occluded by 8 days. When the valves were harvested and 
examined, red clot was prominent.  
 
 
Figure 26: Pellethane valve developed by Hill (image from [107]). 
 
Uflacker developed a monocusp venous valve composed of a polyether urethane leaflet 
attached to a Z-stent (see Figure 27) [110, 134]. The valves were inserted into pigs using a 10-Fr 
sheath into the inferior vena cava. After 1 week, thrombus was found inside the valve’s cusp. 
 
 
Figure 27: Uflacker monocusp valve (image from [110]). 
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Nadzeyka developed a tri-leaflet valve with a self expanding nitinol stent and leaflets 
made of Polyurethane (see Figure 28) [135]. A 10mm valve of this design is able to compress 
into a 10-Fr catheter.  
 
 
Figure 28: Nadzeyka valve (image from [135]). 
 
De Borst developed the sail valve (see Figure 29) [136]. This valve is secured by 2 stents 
and was designed to allow some reflux. To avoid inadvertently sticking to the vein wall, the 
valve’s leaflet never fully opens or closes. This valve is currently undergoing animal testing.   
 
 
Figure 29: Sail valve (image from [136]). 
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Researchers from the University of Akron have reported three generations of prosthetic 
venous valve development [137-140]. Experimental testing for the second and third generation 
valves used a 3.45% dextran solution. Experimental testing applied forward flow rates up to 
1600 mL/min, corresponding to flexing the ankle while standing, to calculate the outflow 
resistance of each valve. A backpressure of approximately 40 mmHg was applied with a column 
of solution 55 cm above the valves to induce reflux. The first generation design underwent seven 
iterations which focused on improving leaflet closure while preventing unwanted leaflet buckling 
(see Figure 30). The second generation design was composed of a rigid frame with a BioSpan® 
(polyether urethane) leaflet that was naturally open (see Figure 31). A 2:1 scale prototype valve 
took 1.38 seconds to close. 1:1 scale valves had a mean reflux volume of 5.83 mL over 
approximately 4 seconds, which corresponds to an average reflux flow rate of 87.45 mL/min, 
and increased the outflow resistance by 1.15-4.66 mmHg*min/L [137]. A computation fluid 
dynamics (CFD) simulation of blood flowing through this valve inside a 12.5774 mm vein with 
an inlet flow rate of 700 mL/min calculated the maximum shear rate to be approximately 7600 s
-1
 
[139]. Concerns with the high residence time of fluid behind the leaflets in the CFD simulations 
of the second generation design prompted the development of the third generation valve design 
(see Figure 32). The third generation design had bowl shaped leaflets which were naturally 
closed and allowed forward flow by separating from the vein walls and moving towards the 
center of the vein. Valves of this design had a mean reflux volume of 0.95 mL over 
approximately 4 seconds, which corresponds to an average reflux flow rate of 14.25 mL/min,  
and increased the outflow resistance by 1.15-4.66 mmHg*min/L [140].  
 
  34   
 
 
Figure 30: First generation prosthetic venous valve prototype developed by researchers from the University 
of Akron (image from [140]). 
 
  
Figure 31: Second generation prosthetic valve developed by researchers from the University of Akron (image 
from [138]). 
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Figure 32: Third generation prosthetic venous valve developed by researchers from the University of Akron 
(image from [140]). 
 
The third generation design from researchers from the University of Akron is similar in 
function to a prototype replacement venous valve made by Sathe which was not further pursued 
because of the high rate of reflux and opening pressure, 1-30 mL/min (over a 25-250 mmHg 
pressure range) and 26.4 mmHg respectively (see Figure 33) [141]. 
 
 
Figure 33: Parabolic shaped valve developed by Sathe (image from [141]). 
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Moriyama developed two prosthetic valves made by electrospinning polyurethane fibers 
onto a stent (see Figure 34) [142]. The valves tested at pressures ranging from 30-150 mmHg 
using a 50 wt% glycerin solution. The first design, named bPVV, had a reflux rate of 0.034 mL/s 
(2.04 mL/min) and increased the outflow resistance of the system by 744.4 mmHg*min/L. The 
second design, named oPVV, had a reflux rate of 0.514 mL/s (30.84 mL/min) and increased the 
outflow resistance of the system by 91.3 mmHg*min/L. The bPVV was selected as the better 
performing valve because it had a smaller stagnation zone and because its distal pressure rose 
more gradually during a pressure change simulating standing ankle flexion.  
 
 
Figure 34: Forward flow of rhodamine solution through the Moriyama valves: bPVV (left) and oPVV (right) 
(image from [142]). 
 
Sathe designed a naturally closed prosthetic venous valve composed of Poly(vinyl-
alcohol) (PVA) cryogel (see Figure 35) [141, 143-145]. This valve had a reflux flow rate less 
than 0.3 mL/min under an applied backpressure ranging from 0-300 mmHg before and after 
500,000 cycles. The valve increased the outflow resistance by 324.6 mmHg*min/L. A CFD 
simulation of the open configuration of this valve in a 10 mm vein with an average inlet flow 
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velocity of 0.27 m/s, corresponding to an inlet flow rate of approximately 1300 mL/min, 
revealed shear rates to exceed 10,000 s
-1
. The valve occluded in an in vitro porcine blood flow 
loop in less than 20 minutes with a 470 mL/min forward flow induced by a roller pump. Two 
valves were implanted into a sheep and were not patent when examined at 5 weeks. It was 
hypothesized that thrombus had formed in response to elevated shear rates from the valve’s 




Figure 35: Sathe valve when closed (left) and open (right) (images from [141]). 
 
Midha developed a naturally open prosthetic venous valve with a lemon shaped orifice 
made with PVA (see Figure 36) [145]. This valve had a mean reflux flow rate of 30.8 and 41.1 
mL/min under an applied backpressure of 75 mmHg before and after 500,000 cycles 
respectively. Small gaps remained after leaflet closure at the corners where the two leaflets 
joined which allowed this amount of reflux. The valve increased the outflow resistance by 7.3 
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mmHg*min/L. A CFD simulation of this valve in a 10 mm vein with an average inlet flow 
velocity of 0.27 m/s, corresponding to an inlet flow rate of approximately 1300 mL/min, 
predicted shear rates up to 3,000 s
-1
. Dye placed behind the leaflets was completely washed out 
under a forward pressure gradient of 75 mmHg. The valve did not occlude in an in vitro porcine 
blood flow loop after 3 hours with a 470 mL/min forward flow induced by a roller pump. Four 
valves were implanted into the external jugular veins of sheep. One valve remained patent at 6 
weeks with the other three valves occluding by week 4. It was hypothesized that thrombus had 
formed in response to elevated shear rates induced by radial buckling of the valves. The base of 
valve had a propensity to radially buckle because of the ovular shape of the shoulder. Further 
experimental testing of the valve revealed the tendency of the valve’s leaflets to prolapse under 
retrograde pressure. The Midha valve is the predecessor to the valve presented in this work.  
 
 
Figure 36: Midha valve (left) with views of the valve cut along the major (middle) and minor (right) axes 
(image from [145]). 
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Remaining Issues 
While a transcatheter prosthetic venous valve has the potential of being an effective 
minimally invasive solution to venous reflux, particularly in the deep venous system, an 
adequate valve has yet to be developed. While venous reflux and outflow obstruction are major 
contributors to the development of CVI, none of the previous valves that have undergone 
experimental testing have been demonstrated to reduce reflux below that seen in individuals with 
venous reflux while also not increasing outflow resistance to venous obstruction levels. Of the 
few valves which have been tested in humans, only one has reported to have remained both 
patent and competent inside an individual for more than a year, but this valve was deemed unfit 
to further use for venous implantation [110]. Thus far prosthetic valves tested in animals or 
humans have commonly reported concerns with: 
 Thrombogenicity 
 Biocompatibility 
 Correct sizing, and subsequent fixation and functionality of the valve   
For a prosthetic venous valve to be developed which is effective in treating individuals 
with CVI, design specifications (design inputs) must first be determined. The Code of Federal 
Regulations (CFR) Title 21 Part 820.30 states that design inputs “ensure that the design 
requirements relating to a device are appropriate and address the intended use of the device, 
including the needs of the user and patient” [146]. Protocols to measure “design outputs in terms 
that allow an adequate evaluation of conformance to design input requirements” are to be 
established [146]. CFR Title 21 Part 820.30 also states, “Design verification shall confirm that 
the design output meets the design input requirements. The results of the design verification, 
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including identification of the design, method(s), the date, and the individual(s) performing the 
verification, shall be documented in the [Design History File]” [146].  
With a foundation of relevant design specifications and verification testing, a prosthetic 
venous valve can be developed which has low thrombogenicity, is biocompatible, is sized 
correctly, is sufficiently competent, does not significantly obstruct forward flow, can function in 
a distensible vein, and so forth. The goals of this work, which are outlined in the following 
chapters, are the following: 
1. Specify design specifications which are necessary for a prosthetic venous valve 
to effectively treat individuals with venous reflux.  
2. Design a prosthetic venous valve capable of meeting all design specifications.  
3. Perform finite element and computational fluid dynamic simulations to analyze 
the valve. 
4. Create and conduct verification tests that will determine if the proposed valve 
meets the required design specifications. 
5. Propose validation tests for the proposed valve in animals and humans. 
Determine where the valve should be placed and specify valve sizes which will 
fit these locations.  
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CHAPTER 2: DESIGN SPECIFICATIONS 
Competency 
The primary function of a prosthetic venous valve is to reduce retrograde flow. Greater 
reflux flow rates have been correlated with increases in symptom severity [32, 147]. Neglén 
measured the time average reflux flow rate for incompetent CFV (n=47), femoral (n=87), and 
popliteal (n=103) deep veins to be 3-3357 mL/min  [32].  A competent prosthetic venous valve 
should have a time average reflux flow rate below 3 mL/min to ensure reflux is reduced below 
pathologic levels.  
A valve must remain competent under all of the potential retrograde pressures it may 
encounter in a vein when an individual is standing. Retrograde pressure in veins is caused 
primarily by the hydrostatic pressure from the column of blood above it which can range from 30 
to 100mmHg [2, 148, 149]. The Valsalva maneuver can increase backpressure up to an 
additional 30mmHg [150]. Thus a venous valve could experience retrograde pressures ranging 
from 30 to 130 mmHg. Applying a safety factor of 1.25 to the maximum pressure, a competent 
prosthetic valve will have a reflux flow rate less than 3 mL/min under backpressure ranging from 
30 to 160mmHg. 
A vein may not be fully distended when the valve is required to close, such as when a 
Valsalva maneuver is performed in the supine position. The diameter of the average CFV at rest 
in the supine position is approximately 17% smaller than during a Valsalva maneuver in the 15% 
reverse Trendelenburg position [151]. Assuming that a valve is sized to fit into a vein when it is 
fully distended, it will need to remain competent when the vein’s diameter is 17% smaller. A 
valve intended to be inserted in a 10mm vein would need to remain competent when its leaflets 
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were constrained inside a 8.5mm tube or smaller. As a lower retrograde pressure will be less 
likely to force a valve closed, this test should be performed under a 30 mmHg pressure head. 
Determining the smallest diameter in which a prosthetic valve can remain competent will also be 
helpful to direct surgeons in inserting an appropriately sized valve into a vein.  
Fatigue Life 
A prosthetic venous valve must remain competent after undergoing extensive cyclical 
loading. It has been predicted that a prosthetic valve would undergo 9 million cycles over the 
course of 10 years in a subject, with valves cycling at a rate of 0.67 Hz during walking [143]. It 
is assumed that a valve produced under good manufacturing practices will have a longer fatigue 
life than a valve produced in laboratory conditions. Thus if a prototype valve manufactured in a 
laboratory can function properly after 5% of the expected number of cycles (500,000), then it can 
be assumed that it would still function after 9 million cycles when produced with good 
manufacturing practices [143]. Thus a competent and fatigue resistant valve would have a reflux 
flow rate less than 3 mL/min under 30 and 160 mmHg of retrograde pressure before and after 
500,000 cycles.  
Closing Time 
Healthy native venous valves typically close in less than 0.5 seconds under retrograde 
pressure, with valves with longer closure times typically being deemed incompetent in clinical 
practice [30-34]. Thus, in addition to restricting retrograde flow, a prosthetic venous valve 
should close in less than 0.5 seconds to be deemed competent.  
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Distal Pressure Rise 
Contraction of the calf muscle pumps blood out of veins which decreases venous 
pressure. Pressure returns to the original level as the vein refills from arterial inflow and valvular 
reflux. This pressure rise is captured by recording the 90% venous refill time (VFT90), which is 
measured by recording the time it takes for venous pressure to rise back to 90% of the initial 
pressure after calf flexion. Individuals with CVI have a VFT90 of less than 30 seconds, while 
normal individuals have a VFT90 greater than 30 seconds [2, 36, 37]. Lower VFT90 
measurements have been correlated with increased symptom severity [18, 37]. Assuming that 
reflux from a healthy venous valve is responsible for 10% or less of the pressure rise, a prosthetic 
valve should see its distal pressure rise to 10% or less of the original pressure 30 seconds after a 
simulated calf flexion.  
Outflow Resistance 
A prosthetic venous valve should not significantly impede venous return to the heart. 





Where    is the pressure difference and   is the flow rate.  
Because veins are distensible, their resistance changes with pressure. Therefore, it is 
important to compare venous resistance at similar pressures. At a forward pressure difference of 
15 mmHg, the average venous resistance in a normal individual calculated by Equation (1) is 10 
mmHg*min/L [48]. Four grades of obstruction, each resulting in an increase in venous 
resistance, have been specified [48]. The lowest grade of obstruction has been reported to 
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increase the average venous resistance by 5 mmHg*min/L at a forward pressure gradient of 15 
mmHg [48]. A prosthetic venous valve should not increase venous resistance as much as venous 
obstruction grade levels do. Thus a prosthetic venous valve should add less than 5 mmHg*min/L 
to the outflow resistance under a forward pressure difference of 15 mmHg.  
Thrombogenicity  
A prosthetic venous valve should have low thrombogenicity. While there is no standard 
method to quantify the degree of a device’s thrombogenicity, items that have been shown to 
promote thrombus formation should be systematically reviewed. Virchow’s Triad proposes that 
thrombus formation in the veins can occur in the presence of stagnant blood, endothelial injury, 
and blood hypercoagulability [152]. Of these three factors of the triad, a prosthetic venous valve 
may contribute to the formation of stagnant blood which could result in thrombus formation. In 
contrast, regions with high shear rates and the material used can increase the risk of thrombus 
formation. Ultimately, the formation of thrombus when the valve is placed in blood will 
determine if it is thrombogenic. 
Stagnation Zones 
Virchow found that stagnant blood increases the risk of thrombosis [152]. Blood behind 
the leaflets of a prosthetic venous valve has the highest risk of being stagnant and clotting. 
Stagnation zones behind the leaflets are unlikely to exist while the leaflets are cycling, such as 
when standing, sitting, or walking. However, when a person is in the supine position, there is 
typically only prograde pressure, so the leaflets may remain open and motionless for long 
periods of time [20]. Venous flow rates of an individual resting in the supine position are 
between 400 to 600 mL/min, which are lower than when standing, further increasing the risk of 
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stagnation zones in this position [137, 153, 154]. To predict if blood behind the leaflets of a 
prosthetic venous valve will clot in the supine position, all of the fluid behind its leaflets should 
wash out under a forward flow rate of 400 mL/min. 
Radial buckling of a valve could create stagnant zones and result in clotting. The valve 
developed by Midha is suspected to have thrombosed for this reason [145]. The average CFV 
diameter at rest in the supine position is approximately 17% smaller than its diameter during a 
Valsalva maneuver [151]. Assuming that a valve is sized to fit into a vein when it is fully 
distended, it must not radially buckle when the vein is at rest and the diameter is smaller. Thus a 
valve should not radially buckle when placed in a tube with a diameter that is 17% smaller than 
the diameter size it is designed to fit in. Thus, a valve intended to fit inside a 10mm vein should 
not radially buckle in a 8.5mm tube.   
Regions of High Shear 
High wall shear rates have been shown to increase platelet activation and binding, 
ultimately leading to thrombus formation and growth [155-157]. High shear rates also lead to 
increased platelet transport and deposition rates [158-160]. The maximum thrombus growth rate 
in human blood occurs at a wall shear rate of roughly 10,000 s
-1
 [161, 162]. Physiologic shear 
rates are generally considered to be below 3500 s
-1
 [163]. The highest shear rate in the valve will 
occur when flow through it is the highest. The peak flow rate through the femoral vein can be up 
to 1600 mL/min, which can occur during ankle flexion while standing or after a Valsalva 
maneuver [137, 151]. To avoid shear induced thrombosis and to have shear rates at physiologic 
levels, the maximum shear rate of the blood flowing through a prosthetic venous valve at a rate 
of 1600 mL/min is required to be below 3,500 s
-1
.   
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Material Biocompatibility 
A valve should be composed of a material that has been shown to be biocompatible and 
have low thrombogenicity. The selected material must demonstrate its biocompatibility by not 
eliciting inflammation or a foreign body reaction, manifesting as fibrous encapsulation, when 
placed in the bloodstream, as well as passing the biocompatibility tests specified by ISO and 
USFDA [164, 165]. While there is no standard method to quantify the degree of a material’s 
thrombogenicity, a material that requires at least as much time for thrombus to form on it when 
exposed to blood as a material currently used in FDA cleared blood contacting devices, such as 
Dacron
TM
, is assumed to have low thrombogenicity.  
Blood Flow Loop 
One way to predict the short term patency and relative thrombogenicity of a valve is to 
place it in an in vitro blood flow loop. Porcine blood has a non-Newtonian flow behavior and 
viscoelasticity similar to human blood [166-168]. Porcine blood will thrombose at low and high 
shear rates, similar to human blood [157, 166, 169]. In addition to similarity, porcine blood has 
been found to thrombose faster than human blood [169]. For these reasons, porcine blood can be 
used to accurately predict a device’s performance in human blood and is advantageous to use in a 
short term test.  
Midha demonstrated that his valve was less thrombogenic than Sathe’s by placing it in a 
flow loop with heparinized (3.5 mL/L) porcine blood flowing at a rate of 470 mL/min: the Sathe 
valve occluded in 18 minutes while the Midha valve was still patent after three hours [145]. A 
prosthetic venous valve should demonstrate that its short term patency in heparinized (3.5 mL/L) 
porcine blood is no worse than the Midha valve under a similar flow rate. Flow rates of this 
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magnitude can occur when an individual is in the supine position, so a valve should be oriented 
in the horizontal direction when verifying this specification for the gravitational force to be in the 
correct direction [137, 153, 154]. 
Deliverability 
The demand by patients and surgeons for a prosthetic venous valve that can be 
percutaneously delivered by a catheter is much greater than one that requires an open surgery. 
Catheters sized 16 Fr (5.3mm) and smaller are commonly used by surgeons and have shown 
better results when used in abdominal aortic aneurysm repair [170]. Thus a prosthetic valve 
should fit inside a 16 Fr catheter or smaller. 
A valve will not function properly if it is placed inside a vein in an incorrect orientation. 
To promote a stable orientation, the length of the portion of the valve in contact with the vein 
wall should be at least 1.5 times the diameter. Hence a valve designed to fit inside a 10mm vein 
should have a 15mm long section in contact with the wall.  
Summary 
The design specifications for a prosthetic venous valve are summarized in Table 5. 
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Table 5: Summary of design specifications for a prosthetic venous valve. 
 Metric Units Specification 
1 Reflux rate under a 30 mmHg pressure head mL/min ≤ 8 
2 Reflux rate under a 160 mmHg pressure head mL/min ≤ 8 
3 Smallest diameter in which the valve remains competent mm ≤ 8.5 
4 Reflux rate under a 30 mmHg pressure head after 500,000 
cycles 
mL/min ≤ 8 
5 Reflux rate under a 160 mmHg pressure head after 500,000 
cycles 
mL/min ≤ 8 
6 Leaflet closing time s < 0.5 
7 Distal pressure rise 30 seconds after a simulated calf 
flexion 
% ≤  10 
8 Outflow resistance added by the valve under a 15 mmHg 
pressure head 
mmHg*min/L < 5 
9 Fluid behind leaflets washes out under 400 mL/min Binary 1 
10 Smallest diameter in which a valve does not buckle mm ≤ 8.5 
11 Maximum shear rate on the valve walls with an inlet flow 
rate of 1600 mL/min 
s
-1
 < 3500 
12 Material does not elicit inflammatory response or foreign 
body reaction when placed in the bloodstream 
Binary 1 
13 Material passes biocompatibility tests specified by ISO and 
USFDA 
Binary 1 
14 Material is less thrombogenic than Dacron Binary 1 
15 Time to occlusion when running heparinized (3.5 mL/L) 
porcine blood in a flow loop 
Hours > 3 
16 Minimum catheter size the valve can fit in Fr ≤ 16 
17 Ratio of the valve length that contacts the vein wall to the 
vein diameter  
NA ≥ 1.5 
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CHAPTER 3: PROPOWED VALVE DESIGN AND FABRICATION 
Material Selection 
Prosthetic venous valves are typically mechanical, bioprosthetic, or polymer valves. A 
polymer valve is desirable because a mechanical valve may not be able to function in a 
distensible vein, and a bioprosthetic valve would be difficult to manufacture in large quantities.  
Poly(vinyl-alcohol) cryogel (PVA) was chosen as the primary material for the proposed 
prosthetic venous valve. PVA is a relatively new and promising biomaterial developed by 
researchers at Georgia Tech [171, 172]. PVA is prepared by combining Poly(vinyl-alcohol) 
pellets with water to obtain a desired wt%, heating in an autoclave at 120 °C until the pellets 
have dissolved. At this point the PVA is in a viscous state and can be used to coat solid objects, 
such as stents, or be injected molded and assume the shape of a desired geometry [141, 145, 
173]. The liquid PVA is then solidified by cross-linking which occurs during freeze-thaw 
cycling.  
PVA meets the requirement of being biocompatible. PVA passed the biocompatibility 
tests specified by ISO and USFDA [165]. When placed in the bloodstream of sheep and rats, 
inflammatory responses and fibrin encapsulation have not occurred [145, 173, 174]. 
Furthermore, medical devices containing PVA have been implanted in humans for over ten years 
without any negative reports [173]. 
PVA meets the requirement of having low thrombogenicity. PVA has been shown to be 
less thrombogenic than Dacron
TM
 when profused with porcine blood [144, 175]. The 
thrombogenicity of PVA can be reduced further by its ability to incorporate and elute anti-
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coagulation drugs, such as citrate [145]. Additionally,  it is difficult for cells to attach to PVA 
because the proteins necessary for adhesion do not easily absorb into it [176]. 
The mechanical properties of PVA can be altered by modifying the solution’s wt% and 
the thermo cycling process [177-188]. Increasing the PVA wt% from 10 to 20 percent has been 
found to increase the ultimate tensile strength and Young’s modulus by up to 192% and 250% 
respectively [177]. The ultimate tensile strength and Young’s modulus have been found to 
increase for each freeze-thaw cycle, with diminishing increases per cycle after the fourth cycle 
[179, 180, 185-187]. For example, Fromageau reported that the mean Young’s modulus for a 10 
wt% PVA solution increased by 77-104 kPa (57-320%) for cycles 1 through 4 and by 16-20 kPa 
(6-7%) for cycles 5 and 6 [179]. Decreasing the rate of freezing and thawing has been found to 
increase the stiffness by up to 340% for the same wt% [178, 179]. One study found the Young’s 
Modulus of PVA having undergone 4 freeze-thaw cycles to remain stable for a period of 7 
months without significant variation, suggesting that the valve leaflets will remain flexible in the 
long-term [183].  
In the present application, the PVA needs to be flexible enough to close under low 
pressures, yet stiff enough to resist prolapse under backpressure. To accomplish these goals, 
prototype valves were made out of 20% PVA and underwent four freeze-thaw cycles. For each 
cycle valves were frozen at -20 °C for at least three hours. The rate of thawing was decreased by 
placing valves in a 4 °C refrigerator instead of at room temperature for at least three hours.  
Geometry 
A prosthetic venous valve was designed to fit a 10mm vein and meet the aforementioned 
design specifications. The valve’s geometry is shown in Figure 37 and Figure 38. The valve has 
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two general regions: the base, which includes the valve’s entry region and shoulder, and the 
leaflets.  
The base of the valve is circular and has an outer diameter slightly smaller than the 
average diameter of the human femoral vein, which decreases the overall bulk of the valve. The 
circularity allows a stent to be placed inside the base of the valve during manufacturing. The 
stent can cause the valve base to expanded inside of a vein and provide the necessary radial 
pressure to fix its position. This expansion decreases the risk of radial buckling and potential 
clotting at the inlet while enabling the valve to fit perfectly into a large range of vein sizes. The 
wall thickness at the base is thick enough to expand with the stent without tearing while keeping 
the overall bulk of the valve low. The base is 15mm long, which ensures that there is only one 
stable orientation for the valve when it is inserted in a vein. The valve shoulder is 0.5 mm wide 
and encourages washout of blood behind the leaflets. The top of the stent is coincident with the 
shoulder which supports the base of the leaflets and reduces the risk of prolapse without 
interfering with leaflet function. Thus the shoulder also helps the stent to be placed correctly 
inside of the valve mold during manufacturing. The circular orifice at the entrance of the base 
transitions into an ellipse to allow the base to support the leaflets. This transition happens in a 
nonlinear manner that keeps the volume of the valve low while not raising the shear rate to 
critical levels with abrupt changes. The orifice of the valve in its unexpanded state is 29 mm
2
 at 
its most constricted point, which occurs at the level of the shoulder, which is 36% of the area of a 
10 mm circular vein. 
The valve’s leaflets are naturally open and are designed to close under retrograde flow. 
The pressure difference between the fluid on the inside and outside of the leaflets during 
retrograde flow causes the leaflets to move inward and close. The leaflets remain closed because 
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of the hydrostatic pressure provided by the column of blood above them. Forward flow causes 
the leaflets to open again.  
Several features were incorporated into the leaflet geometry with the intent to enable 
them to seal during closure while keeping shear rates low when they were open. The elliptical 
orifice at the top of the valve’s base linearly transitions into a lemon shaped orifice by the time it 
reaches half the height of the leaflets after which it remains lemon shaped. The linear transition 
helps keep the shear rate low while decreasing the risk of prolapse. The lemon shaped orifice 
with a 120 degree angle encourages the valve to close properly. The tips of the leaflets are 0.5 
mm thick which allows the ends of the leaflets to be more flexible and seal better while 
decreasing the risk of tearing during removal from the mold during manufacturing. The 128 
degree angle at the outside corner of the leaflets ensures that the smallest thickness of the leaflets 
is no less than 0.5 mm to avoid tearing during mold removal. Various design iterations revealed 
that a decrease in the leaflet diameter along the minor axis of the orifice strongly correlated with 
a decrease in the amount of reflux in a valve. Thus this valve was designed to have this 
dimension as small as possible to decrease reflux while keeping the shear rates at levels below 
those that would increase the risk of platelet activation. The length of the orifice along the inner 
length was set as large as possible to decrease the maximum shear rate.  
To further improve the sealing of the valve, 0.1mm wide and 2.25 mm high slits are 
present at the top of the leaflets at the corners of orifice. These slits enable the leaflets to seal 
better by eliminating any gaps that would otherwise exist at the corners of the leaflets during 
closure. The slits were not made wider or longer because doing so could result in the leaflets not 
lining up correctly during closure. By including these slits in the original geometry, there is no 
need to later create the slits by cutting which could result in a crack at the bottom of the slit that 
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would likely propagate during cycling. The leaflets along the major axis of the orifice flare out to 
ensure that the slits do not lie in the path of high velocity fluid flow, even when the valve base is 
expanded by the stent, which would otherwise result in a spike in the shear rate and increase the 
risk of platelet activation.  
Additional features were incorporated into the leaflet geometry to reduce the risk of 
prolapse. The bottoms of the leaflets along the minor axis of the orifice are the thickest portion of 
the geometry and resist over bending. The leaflets are 10 mm long which is intended to provide a 
friction force great enough to prevent the leaflets from sliding down each other. The internal 
leaflets along the minor axis of the orifice are vertical which was found to help the leaflets seal 
better and be less likely to prolapse than when angled.  
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Figure 37: Drawings and dimensions of proposed valve. 




Figure 38: Isometric views of the proposed valve geometry (left) and halved along the major (middle) and 
minor (right) axes.  
Manufacturing 
Physical valve prototypes of the proposed valve design with and without stents were 
fabricated by injecting 20 wt% PVA into a two-part mold and then temperature cycling for four 
cycles. For valves combined with a stent, the stents were prepared and inserted into the mold 
prior to PVA injection. Details of the mold creation, stent preparation, and subsequent valve 
fabrication are as follows.  
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Mold Creation 
The proposed valve’s geometry was modeled using SolidWorks® v 2012 CAD software 
(Dassault Systèmes Solidworks Corporation, Wltham, MA). The cylindrical base of the valve 
was extruded an additional 5mm which would later assist in the manufacturing process without 
changing the length of the valve. Rigid rapid prototypes of the modified geometry composed of 
FullCure®720 were created using an Objet Eden250
TM
 3D printer (Stratasys Ltd., Edina, MN). 
The prototypes were then placed in a container of the desired mold size and shape, with the 
cylindrical base of each prototype flush against the base of the container. A steel shim measuring 
10mm in diameter and 0.1 mm thick was placed in the leaflet slits of each prototype (see Figure 
39). The steel shims would later ensure the dimensional accuracy of each valve’s slits during 
manufacturing.  
A two part mold was chosen to make the valves to ensure that the valves could be 
removed from the molds without tearing or deflection of the stent. At this point in mold creation, 
four to six toothpicks were placed in the container which would later help align the two mold 
halves during valve fabrication (see Figure 40).   
Polydimethylsiloxane (PDMS) was chosen as the material for the mold primarily for its 
ability to accurately capture the small features of the proposed valve design. After curing, PDMS 
retains its shape in the presence of water and has a high melting point, allowing it to be in contact 
with PVA or cleaned in an autoclave without deforming [189]. PDMS is transparent which 
allows visual detection of unwanted air bubbles during PVA injection. PVA does not adhere to 
PDMS, enabling fabricated valves to be easily removed from the mold [141, 145]. 
PDMS was made from mixing a 10:1 ratio of parts A and B of Sylgard 184® (Dow 
Corning, Midland, Michigan) and then poured into the container around the outside of the rapid 
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prototypes until the bottom 10-15mm was filled. The container was then degassed in a vacuum 
chamber until all bubbles had been expelled from the PDMS. The container was then placed in 
an oven at 45 °C for at least two hours, allowing the top surface of the PDMS to solidify. A thin 
layer of Evercoat 105685 mold release (Evercoat, Cincinnati, Ohio) was poured on top of the 
PDMS around the outside of the rapid prototypes and allowed to dry at room temperature for at 
least 6 hours. The inside of the rapid prototypes and the remainder of the container were then 
filled with PDMS and degassed in a vacuum chamber until all bubbles had been removed. The 
container was then placed in an oven at 45 °C for at least four hours, allowing all of the PDMS to 
fully cure.  
The solidified mold was then removed from the container. Water was used as a lubricant 
as the two halves of the mold were gently pulled away from each other and separated along the 
parting line. The toothpicks were cut at the level of the parting line and removed from the mold, 
allowing the two mold halves to be separated; the rapid prototypes remaining lodged inside the 
top mold half. The top half of the mold was then placed in a beaker of water at 100 °C. The hot 
water served to soften the rapid prototypes allowing them to be removed from the mold using 
forceps without tearing the PDMS. Flutes for the leaflets were created by poking holes through 
the PDMS using a blunt needle. The final valve mold halves are shown in Figure 40.  
5 mm tall cylindrical spacers having the same dimensions as the valve’s base made of 
FullCure®720 were created using an Objet Eden250
TM
 3D printer (Stratasys Ltd., Edina, MN). 
During valve fabrication, spacers were placed in the bottom of each valve cavity to help the 
cylindrical mold geometries be concentric (see Figure 41). This also eliminated the presence of a 
parting line inside of the valves, decreasing the risk of clotting inside of the valves due to 
coagulation of blood caught in this region or a jump in the shear rate due to the sharp change in 
  58   
 




Figure 39: Views of rapid prototype with steel shim and PVA valve on top of cylindrical spacer from the front 
(top) and side (bottom). 
 
  
Figure 40: Venous valve mold (left). Individual mold halves (right). 
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Figure 41: Bottom of mold prior to spacers being inserted (Left). Bottom of valve mold with three of the four 
spacers inserted into the mold (Right). 
 
Stent Preparation 
When the proposed valve is implanted in an animal or human it will be fixed in place by 
a stent. The risk of material related thrombosis increases if the metal stent is in direct contact 
with the blood. Weaver proposed coating a stent with PVA as a way to reduce the risk of 
material related thrombosis [173]. To ensure that each valve’s stent was completely covered by 
PVA, stents were coated with PVA prior to mold insertion by following Weaver’s method [173]. 
A 20 wt% PVA solution was prepared and autoclaved at 120 °C for 25 minutes. Stents were 
expanded with a balloon to 8.5 mm and then dip coated in 20 wt% PVA. Excess PVA inside 
each stent was manually removed using a wire. The stents were then placed in the freezer at -20 
°C and thawed in the fridge at 4 °C three times to solidify the PVA.  
Valve Fabrication 
Prototype valves of the proposed design were fabricated as follows. For valves with a 
stent inside, the stent was first placed inside the mold with its top edge aligned with the future 
valve’s shoulder. Toothpicks were then inserted to constrain the mold halves in the correct 
aligned position. 20 wt% PVA was prepared and injected into the mold through the leaflet flutes 
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and the cylindrical base until all air bubbles had been removed. If present, the stent was 
inspected to make sure it was still aligned with the valve’s shoulder. The spacers were then 
inserted into the base of the mold to constrain the internal cylindrical portions of the mold at 
their bases. The mold then underwent four thermo cycles in a -20 °C freezer and a 4 °C 
refrigerator for at least three hours at each temperature. To avoid dehydration, the valves were 
kept in the molds until after they were finished cycling. The valves were then removed and 
placed in water in preparation for testing.  
A stented valve is shown in Figure 39. Views of the valve when open and closed are 
shown in Figure 42. 
 
  
Figure 42: Proximal views of the prototype valve when open (left) and closed (right). 
 
Intended Use 
The intended use of the proposed valve is to correct venous reflux in individuals with 
chronic venous insufficiency. 
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CHAPTER 4: COMPUTATIONAL ANALYSIS 
Finite Element Model 
A finite element model was created to obtain the geometry of the proposed valve after 
being expanded by a stent into a 10mm vein. The deformed geometry was then used in the 
computational fluid dynamics simulation. 
Material Properties 
As the strain in a PVA valve during its expansion by a stent is expected to be small, the 
material of the valve in this model was assumed to be linearly elastic and isotropic. The Young’s 
modulus of the PVA can be estimated from its manufacturing conditions. Fromageau reported 
that 10 wt% PVA undergoing four freeze-thaw cycles with slow temperature transitions had a 
mean Young’s modulus of 286 kPa [179]. Weaver reported that increasing from a 10 to 20 wt% 
solution can increase the Young’s modulus by 250%, suggesting that the stiffness of the PVA 
used in this application to be approximately 1000 kPa [177]. PVA is nearly incompressible, 
having a Poisson’s ratio between 0.42 and 0.499 [178, 179]. The Poisson’s ratio used for this 
simulation was 0.45. It was assumed that the influences of the stent could be accounted for by 
the boundary conditions so the simulation assumed the material to be homogenous.  
Model Creation 
The original geometry of the proposed valve was halved along its two planes of 
symmetry to reduce the geometry to a quarter of the original (see Table 6). This symmetry was 
later utilized in the finite element simulation to reduce the computational burden without losing 
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accuracy. The modified geometry was then exported into COMSOL and used in the finite 
element simulation. 
 
Table 6: Views of the original and finite element model geometry. 













The following boundary conditions were applied to the model to simulate a stent 
expanding the base of the valve to fit inside a circular vein with a 10 mm inner diameter. The 
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outer wall of the valve’s base was constrained to displace 0.5 mm in the direction normal to its 
surface. The bottom of the valve’s base was also constrained to not move vertically. Symmetry 
was enforced by constraining the portions of the valve on the planes of symmetry to not displace 
in the normal direction. 
Mesh Refinement and Convergence 
Eight meshes for the quarter model were created using COMSOL Multiphysics® v 4.2a 
with characteristics listed in Table 7The smallest dimension on the vein valve is 0.5 mm so the 
smallest element size for the initial mesh was 0.5 mm. Additional meshes with element densities 
2 to 8 times greater than the first mesh were also created. Each mesh used a moderate element 
growth rate of 1.5, a high resolution of curvature of 0.2, and a high resolution of narrow regions 
of 1. The convergence criteria for the iterative solver was 10E-6. 
The simulation was performed and the resulting maximum total displacement magnitude 
was recorded for each mesh (see Figure 43). The mesh with elements size six times as dense as 
the original mesh had the same total displacement as higher density meshes, indicating that this 
mesh was sufficiently refined. The mesh selected for this simulation is shown in Figure 44.  
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Table 7: Element characteristics of meshes constructed during mesh refinement for the finite element model. 
Relative Mesh Density Max Element Size (mm) Min Element Size (mm) 
1 2.5 0.5 
2 1.25 0.25 
3 0.833 0.167 
4 0.625 0.125 
5 0.5 0.1 
6 0.417 0.083 
7 0.357 0.071 




Figure 43: Mesh Convergence for the finite element model. The circled mesh was selected for the finite 

































Relative Mesh Density 
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Figure 44: Selected mesh for the finite element simulation. 
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Results 
The deformed geometry of the finite element model with the valve’s base displaced in the 
normal direction by 0.5 mm, simulating the expansion of the valve by a stent into a 10mm vein, 
is shown in Figure 45 and Figure 46. The maximum principle strain in the valve was 0.473, 
suggesting that the original assumption of a linear elastic modulus was valid for this simulation. 
The leaflets expanded with the shoulder at their base and gradually transitioned back to their 
original geometry 4 mm above the shoulder (see Table 8). After expanding, the minimum orifice 
area of the valve remained approximately 28.4 mm
2
, which is 36.1% of the cross-sectional area 
of the vein. This is within the stenosis range of 30-70% caused by native valves [19, 22].  












0 28.6 36.9 29.0 
1 28.7 32.2 12.1 
2 28.6 29.8 4.2 
3 28.5 28.8 0.9 
4 28.4 28.4 0.0 
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Figure 45: 2D plots of total displacement magnitude on the first (left) and second (right) planes of symmetry 
of the finite element model with the valve’s base displaced in the normal direction by 0.5 mm. Black 
wireframe lines indicate the original geometry. 
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Figure 46: 3D plot of total displacement magnitude in of the finite element model with the valve’s base 
displaced in the normal direction by 0.5 mm. Black wireframe lines indicate the original geometry. 
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Computational Fluid Dynamics Model 
A steady state computational fluid dynamics (CFD) model was created to quantify the 
maximum shear rate of blood flowing through the proposed valve when expanded into a 10mm 
vein at a rate of 1600 mL/min (2.67E-5 m
3
/s) [137, 151]. The maximum shear rate is required to 
be less than 3,500 s
-1
 with this forward flow rate for the valve to meet the design specification 
and reduce the risk of shear induced thrombosis.   
Material Properties 
The working fluid in the simulation was blood, which was assumed to be homogenous 
and incompressible. While blood is inherently non-Newtonian, its viscosity becomes nearly 
constant above a shear rate of 100 s
-1
 [190-192]. As the shear rates encountered in veins in this 
simulation are expected to be above 100 s
-1
, blood was modeled as a Newtonian fluid with a 
viscosity of 0.00345 Pa-s and density of 1056 kg/m
3
 [193].  
The deformed geometry of the valve was assumed to be rigid because the deflection of 
the leaflets with forward flowing fluid observed during experimental testing was small. The vein 
wall was also assumed to be perfectly rigid. Both of these assumptions served to decrease the 
computational burden of the model while still obtaining meaningful results. 
Model Creation 
The 3D locations necessary to create a wireframe of the surface of the expanded valve 
were extracted from the deformed geometry of the finite element simulation (see Figure 47). 
SolidWorks® v 2012 was used to create surfaces from these points which were then lofted 
together by guide curves. The CAD model of the expanded valve is shown in Figure 47. 
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A CAD model of the fluid domain of a circular 10 mm vein was created by modeling a 
10 mm diameter cylinder 80 mm long. Two planes of symmetry were used to reduce this 
cylinder to a quarter of the original geometry. The fluid domain of a vein with the expanded 
valve inside of it was created by subtracting the geometry of the expanded valve from the quarter 
cylinder geometry (see Figure 48). As flow through the inlet was programmed to be fully 
developed, the entry region was 5 mm. The exit region was 5 diameters (50 mm) to prevent any 
flow abnormalities at the outlet from influencing the flow through the valve.  
Boundary Conditions 
A no-slip condition was imposed on the valve and vein walls. Symmetry was enforced by 
constraining the velocity of the fluid on the planes of symmetry to be 0 m/s in the normal 
direction.  
The Reynolds number is defined as:  
   
  ̅ 
 
 (2) 
Where    is the Reynold’s number,   is the density of blood (1056 kg/m3),   is the vein 
diameter (0.01 m),   is the viscosity of blood (0.00345 Pa-s), and  ̅ is the average velocity which 
can be stated in terms of the inlet flow rate: 




Where   is the inlet flow rate (2.67E-5 m3/s), and   is the cross sectional area of the vein 
(7.85E-5 m
2
). Equation (3) evaluates to 0.34 m/s, which is the average velocity at the inlet. By 
combining Equations (2) and (3), the Reynolds number at the inlet was found to be 1040, 
signifying that the flow will be laminar [194].  
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Poiseuille flow was assumed with a velocity profile in a circular tube of [194]: 
  





Where   is the fluid velocity,   is the radial distance from the centerline, and R is the 
radius of the vein (5 mm), and 
  
  
 is the pressure drop. Poiseuille flow through a rigid circular 
tube can be described as [194]: 
   





Equations (4) and (5) can be combined to find the velocity profile in terms of the flow 
rate: 
  
  (     )
   
 (6) 
Equation (6) was used to impose Poiseuille flow on the inlet of a 10 mm diameter vein 
with a 1600 mL/min flow rate (see Figure 48). A pressure of 0 Pa was imposed on the outlet (see 
Figure 48). 
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Figure 47: 3D plot of points extracted from the deformed finite element simulation (left). CAD model of the 
expanded valve created from the extracted points (right). 
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Figure 48: View of entire fluid domain used in the CFD simulation (left). Zoomed in view of the portion of the 
fluid domain inside the deformed valve (right). 
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Mesh Refinement and Convergence 
Six meshes for the fluid domain of the expanded valve were created using COMSOL 
Multiphysics® v 4.2a with characteristics listed in Table 9. A similar approach used in meshing 
the finite element model was used, with the exception that the smallest element sizes were no 
smaller than those used in the finite element mesh. Each mesh used a moderate element growth 
rate of 1.5, a low resolution of curvature of 1, and a moderate resolution of narrow regions of 
0.5. The convergence criteria for the iterative solver was 10E-6. 
The simulation was performed and the resulting maximum velocity magnitude was 
recorded for each mesh (see Figure 49). The mesh with elements five times as dense as the least 
refined mesh had a velocity magnitude within 3% of the highest density mesh, suggesting that 
this mesh was sufficiently refined. The mesh selected for this simulation is shown in Figure 50.  
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Table 9: Element characteristics of meshes constructed during mesh refinement for the CFD simulation. 
Relative Mesh Density Max Element Size (mm) Min Element Size (mm) 
1 2.5 0.5 
2 1.25 0.25 
3 0.833 0.167 
4 0.625 0.125 
5 0.5 0.1 
6 0.417 0.083 
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Figure 50: View of entire selected mesh for the CFD simulation (left). Zoomed in view of the portion of the 
mesh near the deformed valve (right). 
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Results 
Fully developed flow entered the inlet of the valve and transitioned into a jet inside the 
leaflets (see Figure 51). The centerline velocity increased from 0.679 to 1.299 m/s inside the 
valve. Reversed flow up to -0.08 m/s was observed behind the thicker leaflet (see Figure 52 and 
Figure 53). Streamlines revealed that flow was circulating behind the leaflets (see Figure 54).  
The maximum shear rate inside the proposed valve was 2300 s
-1
, which was located on 
the internal wall of the leaflets (see Figure 55). This meets the design specification of having a 
maximum shear rate less than 3500 s
-1
.  
Regions of shear rates below 50 s
-1
 were found behind both leaflets (see Figure 56). It is 
assumed that the shear rate behind the leaflets will increase upon leaflet closure, but 
experimental testing is needed to see if blood will wash out or clot in this region. High and low 
shear rates were not observed in or adjacent to the leaflet's slit, suggesting that this design feature 
may not increase the device's thrombogenicity (see Figure 55 and Figure 56). 
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Figure 51: 2D Contour plots of y velocity on the first (left) and second (right) planes of symmetry. 
  79   
 
  
Figure 52: 2D Contour plots of y velocity on the first (left) and second (right) planes of symmetry. Only 
regions of reverse flow are shown. 
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Figure 53: Wireframe view of fluid domain with a horizontal plane, marked in red, intersecting the domain 9 
mm above the valve's shoulder (left). 2D contour plot of y velocity on this plane (right); reversed flow, 
indicated by shades of blue,  is into the page.  
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Figure 54: 3D plot of streamlines behind the valve's leaflets with (left) and without (right) the valve's internal 
orifice wall and leaflet slit shaded gray. Streamlines indicate that flow is circulating behind the leaflets.  
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Figure 55: 3D view of deformed valve's geometry with the inner walls and leaflet slit highlighted in purple 
(left). 3D contour plot of shear rate on the valve's inner walls and leaflet slit (right). 
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Figure 56: 2D contour plots of shear rate on the first (left) and second (right) planes of symmetry 
emphasizing regions of low shear. Shear rates higher than 50 s
-1
 are dark red.  
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CHAPTER 5: VERIFICATION TESTING 
Preparation 
PVA Tube Fabrication and Valve Fixation 
15% PVA tubes, similar to those used by Sathe, were fabricated to simulate veins during 
the reflux flow rate, smallest competent diameter, distal pressure rise, and outflow resistance 
tests (see Figure 57) [141]. These tubes were 7mm long, 1mm thick and had 10 mm inner 
diameters. Like veins, these tubes distend under pressure and mimic the expansion seen in the 
sinus region of a native valve when the valve inside of them is closed [143].  
The PVA tubes were created by injecting 15 wt% PVA in a mold made of two cylinders 
held concentric by two end caps (see Figure 57). The mold then underwent three thermo cycles 
in a -20 °C freezer and a 20 °C room for at least three hours at each temperature. The tubes were 
removed from the molds after they were done cycling.  
Valves without stents were then placed inside PVA tubes and fixed with Loctite liquid 
super glue (Düsseldorf, Germany) to simulate a valve being fixed inside a vein. After the glue 
had dried, the tubes with valves joined inside were then placed in water in preparation for testing.  
Glycerol Solution Preparation and Properties 
A 40 wt% glycerol solution was prepared to mimic the viscosity of human blood. The 
viscosity of the glycerol solution was measured to be 0.00349 Pa-s by a viscometer. This is 
within 1% of the generally accepted Newtonian viscosity of blood, 0.00345 Pa-s [195]. The 
density of the solution was measured to be 1088 kg/m
3
 using a 100 micropipette and a scale. This 
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solution was used to enhance the accuracy of the reflux flow rate, smallest competent diameter, 
distal pressure rise, outflow resistance, and washout tests. 
 
  
Figure 57: Mold components (left) used to fabricate PVA tubes (right). 
 
Reflux Flow Rate 
Methods 
A test was developed to determine the average reflux rate of a prosthetic valve under 30 
mmHg and 160 mmHg of retrograde pressure (see Figure 58). The proximal end of a PVA tube 
with a valve glued inside was tied to 9 mm inner diameter Tygon tubing. The tubing was 
connected to a reservoir filled with a 40% glycerol solution which was elevated 37 cm above the 
valve’s shoulder to create a retrograde pressure gradient of 30 mmHg. When testing the Midha 
valve, it was discovered that the rate of pressure increase, caused by variations in the time taken 
to get the reservoir to its elevated position, influenced the valve’s competency, with faster rates 
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raising the likelihood of leaflet prolapse. To decrease the variation of the pressure application 
rate, the distal end of the tube was manually squeezed closed after the reservoir was elevated. 
Entrapped air in the tube was then forced through the valve causing its leaflets to open. The tube 
was then released and the full pressure head was immediately applied to the leaflets.  
 
 
Figure 58: Schematic of reflux flow rate test. A column of glycerol induces a pressure to close the valve. The 
reflux flow rate is then measured using a scale and a stopwatch. 
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The average reflux flow rate of the valve over time was then measured using a scale and 
a stopwatch. The scale weighed the amount of reflux with a resolution of 0.01 g. The density of 
the glycerol solution was used to convert grams to mL with the following relation: 




The volume calculated using Equation (7) was then divided by the amount of time taken 
to expel it to find the time average reflux flow rate. Each valve was tested five times to find the 
mean and standard deviation of its reflux flow rate. Each test lasted for at least 1 minute.  
The reservoir was then elevated to 200 cm above the valve’s shoulder to create a 
retrograde pressure gradient of 160 mmHg. The test was repeated as outlined previously, and the 
mean and standard deviation of the reflux flow rate were found for each valve at this higher 
pressure head.  
Results 
The average reflux rate for five valve prototypes was found to be 0.44 ± 0.26 and 0.30 ± 
0.27 mL/min under 30 and 160 mmHg pressure heads respectively (see Table 10 and Figure 59). 
This corresponds to a 99.98-99.99% reduction in the average reflux flow rate compared to that 
without a valve. This suggests that the average reflux rate of the valve will be from 0.30 to 0.44 
mL/min along the entire pressure range of 30-160 mmHg, meeting the design specification of 
less than 3 mL/min.  
Neglen measured the median reflux flow rate of  incompetent CFV, femoral, and 
popliteal venous segments to be 318, 162, and 131 mL/min respectively [32]. Thus the proposed 
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valve would reduce the reflux flow rate in a typical incompetent CFV, femoral, or popliteal vein 
segment by more than 99.63% [32]. 
Table 10: Measured time average reflux flow rates for five valve prototypes at 30 and 160 mmHg. 
 Time Average Reflux Flow Rate (mL/min) ± stdev 
Valve 30 mmHg 160 mmHg 
None 2390 ± 70 3950 ± 270 
A 0.19 ± 0.05 0.09 ± 0.11 
B 0.69 ± 0.40 0.20 ± 0.10 
C 0.40 ± 0.32 0.63 ± 0.07 
D 0.72 ± 0.20 0.52 ± 0.03 
E 0.18 ± 0.14 0.04 ± 0.07 
Average  0.44 ± 0.26 0.30 ± 0.27 
 
 
Figure 59: Average reflux flow rate for the proposed valve at low (30 mmHg) and high (160 mmHg) 
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Smallest Competent Diameter 
Methods 
To determine the smallest diameter in which a valve can be remain competent, a set of 25 
mm long rigid tubes comprised of FullCure®720 were created using an Objet Eden250
TM
 3D 
printer (Stratasys Ltd., Edina, MN) with inner diameters ranging from 6.5 to 10.0 mm in 
increments of 0.5 mm. A rigid tube was placed around the leaflets of a valve glued inside a PVA 
tube. A 30 mmHg pressure head from the 40% glycerol solution was created using the same 
setup as the reflux flow rate test. A valve was deemed competent if its leaflets still closed in spite 
of the constriction of the rigid tube around them. If the valve was still competent, the rigid tube 
was removed and a smaller diameter replaced it. The largest diameter at which the valve leaflets 
did not close was recorded and the diameter 0.5 mm larger was assumed to be the smallest 
diameter in which a valve could remain competent.   
Results 
The leaflets of the valve did not close when constricted by the 7.5 mm rigid tube. This 
suggests that the smallest diameter in which the valve will remain competent is 8 mm. This 
meets the specification of being 8.5 mm or less.   
Fatigue 
Methods 
A flow loop was created to cycle a valve open and closed (see Figure 60). A valve was 
placed on a connector having a 7 mm inner diameter and 9mm outer diameter at its most 
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constricted point (see Figure 61). The valve on the connector was then placed inside transparent 
tubing having an inner diameter of 10mm. This segment of tubing was then connected to the rest 
of the flow loop. The loop was then filled with water. A column of water 55 cm above the valve 
provided a 40 mmHg retrograde pressure to close the valve. A roller pump (Cobe 043605-000, 
Cardiovascular Inc., Avada, CO) caused flow through the inlet of the valve to open the leaflets at 
a specified frequency. The pump rollers only partially displaced the tubing, allowing retrograde 
flow to close the valve whenever the rollers were not inducing full forward flow. Any overflow 
out of the tube above the valve was channeled into a reservoir which had the same elevation as 
the valve. The reservoir then fed back into the roller pump.  
While a venous valve is expected to cycle at approximately 0.67 Hz in an individual 
when walking, an accelerated fatigue test is desirable to reduce the time required to perform the 
test [143]. As increasing the cycling frequency of polymers can reduce their elastic modulus and 
lead to early cycle failure, two accelerated fatigue frequencies were used in this test, 3 Hz and 6 
Hz [196]. 
The time average reflux flow rate of each valve at 30 and 160 mmHg was measured 
before and after undergoing 500,000 cycles. The protocol for the competency test was followed 
with the exception of having the valves secured inside transparent 10 mm inner diameter tubing 
with the connectors mentioned previously instead of PVA tubes. This change was made to allow 
the valves to be visually inspected during cycling to confirm that they were fully opening and 
closing. 
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Figure 60: Schematic of fatigue test. Pulsatile flow is created by a column of water creating a 40 mmHg 
retrograde pressure head which closes the valve and a roller pump which induces forward flow to open the 
valve. The valve closes whenever the roller pump is not inducing full forward flow.  
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Figure 61: Prototype valve before (left) and after (right) being placed on a connector in preparation for 
fatigue cycling or washout test. 
 
Results 
Two valves without any visible defects were selected for the fatigue test. Their time 
average reflux flow rates at 30 and 160 mmHg were measured (see Table 11). The first valve 
was placed in the fatigue flow loop and cycled at 6 Hz for 500,000 cycles. After 500,000 cycles 
the valve was removed from the flow loop and inspected for defects. A crack had formed at the 
base of one leaflet slit which had propagated down the entire length of the leaflet (see Figure 62). 
Reflux testing of this valve revealed that it was no longer competent, having a reflux flow rate 
greater than 3 mL/min under 30 and 160 mmHg of retrograde pressure (see Table 11).  
The cycling frequency was halved for the second valve, which was fatigued at 3 Hz for 
500,000 cycles. After 500,000 cycles the valve was removed from the flow loop and no visible 
fatigue damage was present (see Figure 63). Reflux testing showed that this valve was still 
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competent, having a reflux flow rate less than 3 mL/min at 30 and 160 mmHg pressure heads 
(see Table 11).  
The difference in outcome between the two valves is likely due to the difference in 
fatigue frequencies. Hysteretic heating from the elevated cycle speed of the valve fatigued at 6 
Hz likely reduced the elastic modulus of the PVA and led it to fail at fewer cycles than if cycled 
at the rate of the valve in actual use, approximately 0.67 Hz [141, 196]. This also suggests that 
the valve that underwent accelerated fatigue testing at 3 Hz would have remained competent for 
more than 500,000 cycles if cycled at the rate of the valve in actual use. While it is encouraging 
that the valve cycled at 3 Hz remained competent after 500,000 cycles, more extensive fatigue 
testing is required to determine if this valve design will remain competent for the expected 9 
million cycles in a patient.  
 
Table 11: Time average reflux flow rates for valves before and after 500,000 cycles. 
  Time Average Reflux Flow Rate (mL/min) ± stdev  
Valve           
(Cycle Speed) 
Pressure 0 Cycles 500,000 Cycles Change 
(mL/min) 
A (6 Hz) 30 mmHg 0.73± 0.41 4.61 ± 1.32 3.88 
160 mmHg 0.40 ± 0.65 32.17 ± 7.06 31.77 
B (3 Hz) 30 mmHg 0.01 ± 0.01 0.03 ± 0.06 0.02 
160 mmHg 0.08 ± 0.14 0.04 ± 0.05 -0.04 
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Figure 62: Valve after undergoing 500,000 cycles at 6 Hz. 
 
  
Figure 63: Valve before (left) and after (right) undergoing 500,000 cycles at 3 Hz. 




To determine the average closing time of a valve, it was placed in a pulsatile flow loop 
and video recorded. The valve was constrained in the loop by a tubing connector placed inside of 
its base just below the shoulder. A column of water above the valve provided 40 mmHg of 
pressure to close it, as measured by a pressure transducer proximal to the valve’s shoulder. A 
roller pump (Cobe 043605-000, Cardiovascular Inc., Avada, CO) induced forward flow which 
caused the valve to open at a rate of 3 Hz. A video recording was taken of the valve cycling open 
and closed at a speed of 30 frames per second, a resolution of 0.033 seconds per frame. The 
video recording was then reviewed frame by frame. The number of frames the valve took to 
close was recorded and converted into a closing time. The mean closing time for an individual 
valve was found by averaging the closing time for three different cycles. To meet the design 
requirement of closing in less than 0.5 seconds a valve would need to close in less than 15 
frames.  
Results 
The average number of frames three valves took to close and the corresponding closure 
time are recorded in Table 12. Each valve took 2 frames for the leaflets to close which equates to 
a closing time of 0.067 seconds (see Figure 64). This suggests that the proposed valve design 
meets the design requirement of closing in less than 0.5 seconds.  
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Table 12: Valve closure time results for three valves. 
Valve 
Number of Frames to 
Valve Closure ± stdev Closing Time (s) ± stdev 
A 2 ± 0 0.067 ± 0 
B 2 ± 0 0.067 ± 0 
C 2 ± 0 0.067 ± 0 




Figure 64: Example of Frames used to determine valve closure time. Frame 0 (Left). Frame 2 (Right). 
 
Distal Pressure Rise Test 
Methods 
A test was developed to determine the distal pressure rise of a prosthetic valve after a 
simulated calf flexion. Both ends of a PVA tube with a valve glued inside were tied to 9 mm 
inner diameter Tygon tubing (see Figure 65). A pressure transducer was located distal to the 
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valve. Reservoirs were connected to the Tygon tubing upstream and downstream of the valve. 
The reservoirs were filled with the 40 wt% glycerol solution and elevated 120 cm above the 
valve to create an equilibrium pressure of 95 mmHg, which is a typical venous equilibrium 
pressure near the calf [2]. The pressure transducer was calibrated to read 95 mmHg when the 
system was in equilibrium. 
The ejection of blood out of the calf by contraction of the calf muscle was simulated by 
lowering the reservoir connected to the proximal end of the valve until the pressure transducer 
read 0 mmHg. This reservoir was then quickly raised back to its original height. The reading on 
the pressure transducer was recorded after 30 seconds. As the results of this test will be highly 
dependent on the diameter of the tubing used, the valve was tested in tubing slightly smaller than 
the femoral vein to determine the worst case scenario results.  
 
 
Figure 65: View of valve and pressure transducer in the distal pressure rise test. 
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Results 
The distal pressure rise test was performed with and without a valve present. 30 seconds 
after the simulated ankle flexion, the system without a valve present had returned to the 
equilibrium pressure of 95 mmHg. This showed that the system could mimic the quick rise in 
distal pressure seen in individuals with incompetent valves.  
A valve was then tested in this system three times. The average distal pressure rise 30 
seconds after the simulated ankle flexion was 7 ± 1 mmHg, which was approximately 7% of the 
equilibrium pressure, which satisfies the specification of rising 10% or less.    
Outflow Resistance 
Methods 
A test was created to measure a valve’s outflow resistance (see Figure 66). The distal end 
of a PVA tube with a valve glued inside was tied to 9 mm inner diameter tubing. The tubing was 
connected to a reservoir filled with 40% glycerol which was quickly elevated 19 cm above the 
valve’s shoulder to create a forward pressure gradient of 15 mmHg. A stopwatch and a graduated 
cylinder were used to measure the average forward flow rate through the valve. The amount of 
fluid dispelled through the valve into the graduated cylinder was determined visually, as the 2 
second response time of a scale was too slow to provide an accurate measurement. 
The total outflow resistance was calculated by dividing the pressure gradient by the 
measured flow rate. This test was performed without a valve to determine the resistance inherent 
in the system. The resistance added by the valve was calculated by subtracting the resistance 
inherent in the system from the total outflow resistance.  
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Figure 66: Schematic of outflow resistance test. A 15 mmHg pressure head is induced by a column of glycerol 




The measured flow rates, total outflow resistances, and resistance added by the valves 
were found for five individual valves and are shown in Table 13. The outflow resistance inherent 
in the system was 9.1 mmHg*min/L, which is similar to the resistance of a healthy vein at this 
pressure gradient, 10 mmHg*min/L [48]. The average resistance added by the valves was 2.3 ± 
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1.0 mmHg*min/L. This suggests that the valve will not significantly impede blood flow back to 
the heart and that it meets the design specification of increasing the outflow resistance by less 
than 5 mmHg*min/L (see Figure 67).  
 
Table 13: Measured average flow rates, total outflow resistances, and resistance added by the valves results. 
 Average Flow Rate 
(mL/min) ± stdev 
Total Outflow Resistance 
(mmHg*min/L) ± stdev 
Outflow Resistance Added by 
Valve (mmHg*min/L) ± stdev 
No Valve 1651 ± 76 9.1 ± 0.42 NA 
A 1161 ± 65 13.0 ± 0.7 3.9 ± 0.7 
B 1426 ± 37 10.5 ± 0.3 1.4 ± 0.3 
C 1417 ± 53 10.6 ± 0.4 1.5 ± 0.4 
D 1333 ± 46 11.3 ± 0.4 2.2 ± 0.4 
E 1281 ± 66 11.7 ± 0.6 2.6 ± 0.6 




Figure 67: Comparison of outflow resistance added by the valve and venous obstruction Grade 1 at 15 mmHg 






































A closed flow loop was created to determine if all of the fluid behind the valve’s leaflets 
washes out under a flow rate of 400 mL/min (see Figure 68). A valve was placed on a connector 
and fixed inside a transparent tube with a 10 mm tube similar to the fatigue test (see Figure 61). 
This segment of tubing was then connected to the rest of the flow loop. The loop was then filled 
with a 40% glycerol solution. To visualize the flow of the fluid behind the valve’s leaflets, a 
green hydrophilic dye, McCormick Green Food Color (McCormick & Company, Sparks, MD), 
was injected behind the valve’s leaflets (see Figure 69).  A roller pump (Cobe 043605-000, 
Cardiovascular Inc., Avada, CO) caused an average flow rate of 410 mL/min through the inlet of 
the valve. The pump rollers displaced the tubing enough to prevent any retrograde flow. The 
fluid then flowed into a closed reservoir, which fed back into the roller pump. If the dye is 
completely washed out from behind the leaflets then the valve is considered to have passed this 
test. 
Results 
The dye washed out from behind the leaflets in a few seconds when the roller pump was 
turned on (see Figure 69). This suggests that flow behind the valve leaflets will not become 
stagnant under the low flow rate encountered in the supine position. 
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Figure 68: Flow loop used for the washout test. 
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Figure 69: Green hydrophilic dye behind the leaflets (left) completely washes out under a forward flow rate of 




25 mm long rigid tubes comprised of FullCure®720 were created using an Objet 
Eden250
TM
 3D printer (Stratasys Ltd., Edina, MN) with inner diameters ranging from 6.5 to 10.0 
mm in increments of 0.5 mm. These tubes were used to determine the smallest diameter a valve 
could be inserted into without radially buckling for a prototype valve without a stent. The valve 
was inserted into a tube using and then expanded with a 10 mm balloon. The balloon was then 
removed and the base of the valve was visually inspected for radial buckling. The largest 
  104   
 
diameter at which the valve buckled was recorded and the diameter 0.5 mm larger was assumed 
to be the smallest diameter a valve could be in without buckling.   
Result 
A prototype valve without a stent was able to decrease in diameter from 9 to 7mm (22%) 
without radially buckling. 7mm was the smallest diameter the valve could be inserted into 
without buckling as it radially buckled in a 6.5 mm tube (see Figure 70). This is 1.5 mm smaller 
than the 8.5mm required by the specification. A 10 mm Midha valve was found to radially 
buckle in a 9.5 mm tube, so it would not have met this specification.   
 
  
Figure 70: Valve inserted into a 7 mm inner diameter rigid tube does not radially buckle (left) but buckles in 
a 6.5 mm tube (right). 
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Blood Flow Loop Test 
Methods 
A blood flow loop similar to that used by Midha was erected (see Figure 71) [145]. A 
stented valve was placed inside a section of 10 mm inner diameter transparent tubing. A 10 mm 
balloon was inflated to expand the stent to fit the tubing. Clamps constrained this section of 
tubing to ensure that the valve was oriented horizontally. Whole porcine blood was heparinized 
(3.5 mL/L) and put into the flow loop. A roller pump (Cobe 043605-000, Cardiovascular Inc., 
Avada, CO) caused the blood to flow through the inlet of the valve at an average of 510 mL/min. 
The blood then dispensed into an open reservoir which fed into the roller pump. Blood flowed 
through the loop for three hours. At this point the section of tubing containing the valve was 
removed and inspected for clots. The cessation of flow from the tubing into the reservoir would 
indicate that a clot had formed in the flow loop and would signal that the test should be stopped 
prematurely. 
 
Figure 71: Blood flow loop. 
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Results 
A stented valve was placed in the blood flow loop for three hours. The section of tubing 
containing the valve was removed and lightly rinsed with water to drain it of blood. No clots 
were present inside the valve (see Figure 72) or behind its leaflets (see Figure 73). Small clots 
were beginning to form around the tubing connectors, demonstrating that clot formation was 
possible in this system with the porcine blood used. This test demonstrated the short term 




Figure 72: View valve’s inlet after being in the blood flow loop for three hours. 
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The minimum catheter size a valve can fit in can be estimated as follows. If a prosthetic 
valve is crimped and perfectly fits into a cylindrical catheter without any gaps or lengthening of 
the valve, the volume of the valve in terms of its crimped radius and length would be:  
        (8) 
Where V is the volume of the valve in mm
3
, r is the crimped radius of the valve, and L is 
the length of the valve. The relationship between French size and the internal radius of a catheter 
in mm is: 
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    (  ) (9) 
Where F is the French size of the catheter and r is the radius of a catheter in mm. 





As the radius of the catheter is the same as the crimped radius of the valve, Equation (10) 
can be substituted into Equation (8) to obtain: 





  (11) 
Equation (11) can be rearranged to find the French size in terms of the volume and length 
of the valve: 




Equation (12) can be used to estimate the minimum French size of a catheter that a valve 
can be placed into. As the direct calculation will likely include a fractional part, a more realistic 
estimate will be the result rounded up to the next whole number. 
To verify that the valve meets the specification of fitting inside of a 16 Fr (5.3 mm) 
catheter, a 25 mm long rigid tube made of FullCure®720 was created using an Objet Eden250
TM
 
3D printer (Stratasys Ltd., Edina, MN) with an inner diameter of 5.3 mm. A valve could then be 
placed inside this tube to verify that it can fit inside a 16 Fr catheter.  
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Results 
The CAD model of the proposed valve was analyzed and its volume and length were 
found to be 438 mm
3
 and 25 mm respectively. The minimum French size the valve could fit into 
was calculated using Equation (12) to be 14.2, making 15 Fr its actual estimate when rounded up 
to the next whole number. A prototype valve was placed inside the 16 Fr tube to verify that it 
meets the specification (see Figure 74). 
 
Figure 74: 10mm valve placed in 16 Fr (5.3 mm) inner diameter tube. 
Summary 
Table 14 summarizes the design specifications and the results of the verification testing 
that was performed. The proposed valve met every design requirement for which verification 
testing was performed.  
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Table 14: Summary of design specifications and verification testing results for the proposed venous valve. 
 
Metric Units Specification 
Valve 
Performance* 
1 Reflux rate under a 30 mmHg pressure 
head 
mL/min ≤ 8 0.44 ± 0.26 
2 Reflux rate under a 160 mmHg pressure 
head 
mL/min ≤ 8 0.30 ± 0.27 
3 Smallest diameter in which the valve 
remains competent 
mm ≤ 8.5 8
Ψ
 
4 Reflux rate under a 30 mmHg pressure 
head after 500,000 cycles 




5 Reflux rate under a 160 mmHg pressure 
head after 500,000 cycles 




6 Leaflet closing time s < 0.5 0.067 ± 0 
7 Distal pressure rise 30 seconds after a 
simulated calf flexion 
% ≤  10 7 ± 1 
8 Outflow resistance added by the valve 
under a 15 mmHg pressure head 
mmHg*min/L < 5 2.3 ± 1.0 





10 Smallest diameter in which a valve does 
not buckle 
mm ≤ 8.5 6.5
Ψ
 
11 Maximum shear rate on the valve walls 
with an inlet flow rate of 1600 mL/min 
s
-1
 < 3500 2300 
12 Material does not elicit inflammatory 
response or foreign body reaction when 
placed in the bloodstream 
Binary 1 1 
13 Material passes biocompatibility tests 
specified by ISO and USFDA 
Binary 1 1 
14 Material is less thrombogenic than Dacron Binary 1 1 
15 Time to occlusion when running 
heparinized (3.5 mL/L) porcine blood in a 
flow loop 
Hours > 3 > 3
Ψ
 
16 Minimum catheter size the valve can fit in Fr ≤ 16 16 
17 Ratio of the valve length that contacts the 
vein wall to the vein diameter  
NA ≥ 1.5 1.5 
* Mean ± Standard Deviation  
Ψ
 N=1  
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CHAPTER 6: PROPOSED VALIDATION TESTING AND SIZING  
Purposes 
While verification testing confirmed that the proposed valve met all the design 
specifications for an effective prosthetic venous valve, validation testing is needed to confirm 
that the valve meets the needs of the user with its intended use [197].  
Animal Testing 
The long term safety, patency, and relative thrombogenicity of a proposed valve in a 
human can be inferred by testing it in an animal model. Replacement venous valves have 
historically been tested in sheep, pigs, dogs, and goats with complications, if occurring, such as 
valve migration, thrombus formation, neointimal hyperplasia, fibrous encapsulation, and 
inflammation developing within 12 weeks [12, 94, 107-110, 115, 117, 118, 121, 125, 127-129, 
134, 145]. In animal studies longer than 12 weeks, complications did not develop or worsen after 
12 weeks [115, 127, 131].  
The ovine external jugular vein (EJV) is a potential site of implantation to test the 
proposed valve. This vein has an average diameter of 12.0 with a standard deviation of 1.4 mm, 
which is comparable to the average size of the human femoral vein, 11.84 mm [115, 151]. 
Valves are naturally present in the sheep EJV and close to prevent peripheral venous 
hypertension when hydrostatic or central venous pressure increases [198]. Thus a prosthetic 
venous valve placed in this location is expected to periodically cycle, such as when the sheep 
drops its head below its heart while eating.  
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Proposed Methods (Animal Study) 
A study was designed to evaluate the patency, fixation, and biocompatibility of the 
proposed prosthetic venous valve in the external jugular veins (EJV) of sheep. In studies where 
replacement valves remained patent for 12 weeks, 9-16 sheep were used [121, 131]. For this 
study to be comparable to these studies, 12 sheep may be used to account for potential biologic 
variance.   
Each sheep will have two valves surgically implanted, one in each EJV. Each sheep will 
be anesthetized prior to surgery. To implant the valves, approximately 2 inches of each EJV will 
be exposed by a longitudinal incision. A stented valve will be inserted into each vein through a 
small venotomy and expanded by a balloon until fixed in position. Each venotomy and 
longitudinal incision will be closed with sutures. Each sheep will then recover from the 
anesthesia and be given local analgesics to minimize pain and discomfort.  
To decrease the risk of thrombosis during and after surgery, the following regiment of 
anticoagulation will be given to each sheep. During manufacturing valves will be impregnated 
with less than 5 mL of 3.2% sodium citrate which will be slowly expelled after implantation. 
During surgery, each sheep will receive 100 U/kg of heparin. After surgery, 325 mg of buffered 
aspirin will be daily administered to each sheep. 
Valve patency and position, and biocompatibility will be the primary endpoints of the 
study. The study will last for a maximum of 12 weeks. The position of and flow through each 
valve will be evaluated every two weeks by venogram, as described by Midha [145]. The sheep 
will be anesthetized during each venogram. Sheep will be euthanized after 12 weeks or when 
both of its implanted valves are no longer patent. The valve will be deemed biocompatible if 
inflammation or fibrin encapsulation does not occur. Each sheep will be observed daily for any 
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signs of discomfort or abnormal behavior. If a sheep loses more than 20% of its baseline weight 
prior to surgery it will be euthanized to prevent unnecessary distress.  
After a sheep is sacrificed, the vein segments containing the implanted valves will be 
removed. Each segment will be gently washed with saline to decrease the risk of post-mortem 
clotting and placed in formalin for preservation. The valves will be examined by gross sectioning 
and histology performed as described by Midha [145].  
Protocol 2002062-102415BA, which details the above procedures, was approved by the 
Institutional Animal Care and Use Committee of Emory University on October 24, 2012.  
Human Testing 
If the proposed valve meets the primary endpoints of animal testing, the valve will then 
be ready for human testing. The following describes the recommended protocol to implant and 
evaluate the valve in human subjects. 
Location 
Minimum Distance Between Valves 
The minimum distance between two prosthetic valves placed in the same vein segment 
will be determined by the minimum pressure needed to close an individual valve. The proposed 
valve will flutter open and closed when a low level of backpressure is applied, resulting in a 
pulsing sensation. As flow pulsation in the saphenous vein has been correlated with increased 
symptom severity in individuals with CVI, leaflet fluttering should be avoided [199].   
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The average minimum closing pressure of the proposed valve was found by visually 
measuring the minimum height of water needed to close the valve and calculating the applied 
hydrostatic pressure. Three valves each underwent this procedure three times and the mean and 
standard deviation for the minimum water height and corresponding hydrostatic pressure 
required to close each valve is shown in Table 15. The mean minimum closing pressure for three 
valves was approximately 10 mmHg, which would occur under a column of blood (density = 
1056 kg/m
3
) 13 cm high [193]. This suggests that valves of this design should be implanted at 
least 13 cm apart.  
 
Table 15: Experimental results of the minimum height of water required to close a valve. The applied 
hydrostatic pressure and the height of blood needed to cause this pressure (equivalent to the minimum 
distance between valves in a vein) were calculated.  
Valve Minimum Water Height 
Needed to Close the Valve 
(cm) (mean ± stdev) 
Hydrostatic Pressure 
(mmHg) (mean ± stdev) 
Minimum Distance Between 
Valves in a vein (cm) 
A 13.7 ± 0.6 10.1 ± 0.4 13 ± 1 
B 13.3 ± 0.6 9.8 ± 0.4 13 ± 1 
C 13.3 ± 0.6 9.8 ± 0.4 13 ± 1 
Average 13.4 9.9 13 
 
Potential Vein Segments and Implantation Sites 
Labropoulos recorded the number of refluxing segments in the deep veins for 94 patients 
with venous ulcers (see Table 16) [42]. Reflux in the Popliteal vein accounted for the largest 
percentage of refluxing segments (42%), followed by the CFV (29%), calf veins (17%), and the 
femoral vein (12%). The deep veins in the calf are approximately 2-3 mm in diameter and are 
much smaller than the other deep veins which are roughly 9-14 mm in diameter [200]. To reduce 
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the number of different valve sizes to be produced and keep manufacturing costs low, the CFV, 
femoral, and popliteal veins will be the sites of implantation for the proposed valve. Valves that 
fit in these three veins will be able to correct 83% of the refluxing deep venous segments for 
individuals with venous ulcers.  
 
Table 16: Occurrence of reflux in deep vein segments in ulcerated limbs (data from [42]). 
Vein Number of Refluxing Segments Percent  
CFV 26 29 
Femoral 11 12 
Popliteal 37 42 
Calf Veins 15 17 
 
In the surgical correction of deep venous valves, usually only one incompetent valve is 
corrected with sites of repair being the most proximal valve in the CFV, femoral, or popliteal 
vein [43, 98, 99, 201-204]. While the majority of valve repairs have been in the CFV, surgical 
correction of the popliteal vein is becoming more popular among surgeons [154]. However, 
Tripathi found a statistically significant increase in ulcer healing rate when the surgical 
correction of deep venous valves was performed in multiple venous segments compared to 
singular valve repair, irrespective of the site of valve repair (see Table 17) [45]. This suggests 
that reflux should be corrected in each refluxing vein segment to achieve the greatest symptom 
improvement. However, it may be prudent to implant valves only in the CFV in the initial 
clinical trial to avoid the development of significant complications in the event of valve 
occlusion. If validation testing shows that the proposed valve is unlikely to clot in the CFV, 
valves may also be placed in incompetent femoral and popliteal veins.  
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Table 17: Comparison of ulcer healing rates for the surgical correction of single and multiple deep venous 
valves with primary and secondary incompetence (data from [45]).   
 % Ulcer Healing  
Incompetence 
Type 
Single valve repaired Valves repaired in 2-3 
incompetent venous segments 
Difference 
Primary 57 72.9 15.9 
Secondary 46 54.7 8.7 
 
A functioning valve in the most proximal end of an incompetent vein would likely restore 
competence to a greater portion of the vein than when placed in a more distal location. Native 
valves are typically located 0.5-2 cm distal to junctions with other veins and periodically in 
between (see Figure 75) [205]. Assuming validation testing shows that the proposed valve is 
unlikely to clot in the CFV, it is suggested that the replacement valve be placed 0.5-2 cm below 
the most proximal end of each refluxing CFV, femoral, and popliteal vein (see Figure 75). After 
the initial valve is placed, Doppler ultrasound may be used to determine if additional valves need 
to be implanted distal to the initial valve. When reflux greater than 3 mL/min is present during a 
Valsalva maneuver, additional valves may be placed between vein junctions within the same 
vein segment with a minimum of 13 mm between valves to ensure that these additional valves 
can close. Prior to implantation, a specific implantation site for the most proximal valve in each 
incompetent vein segment should be determined by venogram or ultrasound. 
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Figure 75: Schematic of deep vein junctions between the groin and below the knee (image from [32]) Stars 
indicate the proposed locations of the prosthetic valve to be implanted in the femoral and popliteal veins. 
 
Proposed Methods (Human Study) 
Sample Size 
As the data to be analyzed is paired and will not be normal, the Wilcoxon signed-rank 
statistic for paired data may be used to determine statistical significance compared to baseline 
values [206, 207]. This statistic is commonly used to determine significance in VCS scores and 
hemodynamic parameters [38, 52].  
  118   
 
G*Power was used to determine the sample size with the following inputs [208, 209]: 
The significance level, also referred to as the type 1 error alpha, was set to 0.05. As the VCS 
score changes in discrete increments of 1, the effect size to be discerned in the test was set to 1. 
The desired power of the test is 0.95. With the aforementioned criteria, the suggested sample size 
is 15 subjects. As there is a risk of losing contact with some subjects, the actual number of 
subjects recruited for the study may be more tha 15 to ensure that enough subjects remain in 
contact for statistical significance to be determined.  
Inclusion Criteria 
Subjects selected for the study will have a severe case of CVI that is resistant to 
conservative treatment, specifically compression stockings, with a VCS score of 7 or higher. 
Each will have the presence of deep venous reflux, with reflux lasting more than 2 seconds in the 
CFV and have a VFI 10 mL/s or greater.   
Exclusion Criteria 
Potential subjects will be excluded based on the following criteria: The presence of 
venous obstruction of any grade level, as manifested by an outflow resistance 15 mmHg*min/L 
or greater, as venous stenting would be a more appropriate procedure [48]. Occurrence of 
thrombosis in the last 24 months, as this would increase the likelihood of thrombosis occurring in 
the valve clotting. Individuals with the presence of another disease requiring treatment such as 
diabetes or another cardiovascular disease. Individuals with a high risk of developing 
complications from heparin or aspirin.  
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Implantation 
Prior to implantation, subjects will have their VCS score, VFI, AVP, EF, and outflow 
resistance measured. Prior to the procedure, the diameter of the CFV where the valve will be 
implanted may be measured using Doppler ultrasound. The guidelines found in Chapter 6 of this 
manuscript regarding valve sizing will be followed to determine the size of valves to be 
implanted. Patients will be given local anesthesia and 5000 units of heparin in preparation for the 
procedure [88]. Guided by ultrasound, a valve may be percutaneously delivered by catheter 0.5-2 
cm below the most proximal end of the CFV and expanded with a balloon. Additional valves 
may be implanted in the CFV at least 13 cm apart, to ensure that valves will be able to close, at 
locations where Doppler ultrasound reveals reflux to exceed 3 mL/min when patients perform a 
Valsalva maneuver. Patients will take 81 mg of Aspirin daily indefinitely after implantation to 
reduce the risk of thrombus formation [88]. 
Endpoints 
Primary endpoints to evaluate the safety and functionality of the proposed valve after 
being implanted in a human are as follows:  
 Valve patency, which may be determined by Doppler ultrasound in the supine position. A 
few prosthetic venous valves implanted into humans have been reported, with most 
failing to demonstrate long term competency and patency [110, 116, 124, 126]. Of these 
valves, the longest reported to remain competent and patent was 16 months, which serves 
as a benchmark for other prosthetic venous valves [126]. 
 Valve competency, which may be determined by Doppler ultrasound during a Valsalva 
maneuver with the subject in the 15% reverse Trendelenburg position. Valves taking 
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longer than 0.5 seconds to close are typically deemed incompetent in clinical practice, 
thus the valve will be deemed competent if it closes in less than 0.5 seconds [30-34]. The 
benchmark for competency is 16 months [126]. 
 Valve position, as determined by ultrasound. A valve that is not fixed in position after 
implantation has the risk of migrating to the lungs.   
 Valve biocompatibility, as determined by the absence of inflammation or fibrin 
encapsulation.  
Secondary endpoints to evaluate the valve’s impact on a subject’s symptoms and vein 
hemodynamics, and to allow comparison to other treatments of CVI are as follows:  
 VCS score, which will quantify the change in severity of a subject’s symptoms and allow 
comparison with other treatments for CVI. For example, Cesarone reported the average 
VCS score in 31 individuals with CVI to decrease from 8.4 to 5.7 after eight weeks when 
treated with compression therapy [61]. As VCS scores are discrete, the proposed valve 
would be as effective for treating CVI as compression stockings if the average VCS score 
in the proposed human study is 6 or less after 8 weeks.  
 AVP, which may be determined by needle in the dorsal foot vein during tiptoe exercises 
with the methods used by Nicolaides [18]. This will quantify any changes in a subject’s 
venous hypertension, which is the primary characteristic of individuals with CVI.  
 VFI, which may be measured by PG with the methods used by Araki [36]. This will 
quantify the effectiveness of the proposed valve to reduce venous reflux.  
 EF, which may be determined by PG with the methods used by Araki [36]. This will 
determine if the valve influences the effectiveness of the calf muscle pump, which is one 
of the main contributing factors to venous hypertension in CVI.  
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 Outflow resistance, which may be determined by PG and a needle in the dorsal foot vein 
with the methods used by Neglen [48]. This will detect if an outflow obstruction, another 
contributor to the venous hypertension seen in individuals with CVI, has developed in a 
subject. An outflow resistance above 15 mmHg*min/L would indicate that something, 
such as the valve or DVT, has obstructed venous outflow and that additional corrective 
procedures, such as venous stenting, may need to be proscribed.  
Primary and secondary endpoints will be measured at baseline, 8 weeks, as well as 6, 12, 
and 18 months after implantation.  
Valve Sizing 
Determining Vein Diameter for Sizing 
To determine the range of vein sizes in which the proposed valve can fit, a baseline 
reference for the vein diameter must first be defined because veins are distensible. Sizing the 
valve in terms of a vein’s fully distended diameter is advantageous so that fixation by stent 
expansion can be ensured. In this chapter,    will refer to the fully distended diameter of the 
vein. 
Minimum Vein Diameter 
The smallest diameter in which a valve can remain competent will determine the 
minimum diameter,     
 , it can be implanted into. The distensibility of a vain,  , can be 
quantified by dividing a vein’s    by the diameter of the vein at rest,      : 




     
 (13) 
The     
  a valve can be placed in is  
    
        (14) 
Where SCD is the smallest diameter in which the valve can remain competent. The SCD 
of the 9 mm valve design that underwent verification testing was 8 mm. Assuming the ratio of 
valve diameter to SCD remains constant when the valve is scaled in size, Equation (14) can be 
stated in terms of the original outer diameter of the valve,    : 
    
          (15) 
Equation (15) can be used to find the smallest    in which a valve can be placed and 
remain competent and is a function of the vein’s distensibility and the initial diameter of the 
valve.  
Maximum Diameter 
The largest diameter in which a valve can remain competent without tearing during stent 
expansion will determine the maximum vein diameter,     
 , it can be placed in. Weaver defined 





Where    is the final circumference of the test section and    is its initial circumference. 
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Where    is the final diameter of the circular test section and    is its initial diameter. 
Solving Equation (17) for the final diameter yields: 
     √  (18) 
For the present application,    would be equal to     
 ,    the valve's unexpanded 
diameter    , and   the allowable stretch ratio. Weaver determined that a cylindrical 20 wt% 
PVA section opened at a slow rate will fail at an average stretch ratio of 3.08 [177]. Dividing by 
a safety factor of 1.25 yields a safe stretch ratio of 2.46. It is assumed that a stented valve needs 
to be capable of expanding to a diameter at least 15% larger than the vein it is inserted into to be 
fixed in place [68]. These constraints can be imposed on Equation (18):  
        
     √     (19) 
Solving for     
 , Equation (19) becomes: 
    
         (20) 
Equation (20) is only a function of the initial diameter of the valve and can be used to 
find the largest    a valve can be placed into and remain fixed in position with low risk of 
tearing. 
 The risk of leaflet prolapse increases the larger the valve expands. An experimental test 
was performed to ensure that the leaflets of a valve will not prolapse when expanded to 1.4 times 
its initial diameter. Using Equation (20),     
  for a 9 mm valve was calculated to be 12.6 mm 
(see Figure 76). A stented 9 mm valve was then expanded inside a 13 mm tube, the nearest 
available sized tubing larger than its     
 . A pressure head of 160 mmHg was applied proximal 
to the valve with a column of water 220 cm above the valve's shoulder. The leaflets closed 
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without prolapsing. This suggests that     
  is limited more by the risk of tearing than by 
prolapse for this valve design and that the leaflets will not prolapse if Equation (20) is followed.  
 
  
Figure 76: Views of a stented 9 mm valve expanded to 12 mm (approximately the size of the largest vein 
diameter this valve is suggested to be placed in) compared to an unexpanded valve. 
 
Stent Size 
It is assumed that a stented valve needs to be capable of expanding to a diameter at least 
15% larger than the vein it is inserted into to be fixed in place [68]. Thus the fully expanded 
diameter of a valve’s stent,       , needs to be 15% larger than the valve’s     
 , which can be 
found by modifying Equation (20):  
                   (21) 
Which simplifies to: 
              (22) 
Valve Sizing for Sheep 
Bia measured the mean cross sectional area of the sheep EJV to increase by 2%, which 
corresponds to a diameter change of less than 1%, as the internal pressure increased from 75 to 
130 mmHg [210]. This suggests that the distensibility of the sheep EJV can be neglected. Thus 
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   for a sheep EJV is the diameter of the pressurized vein at rest which can be measured, such as 
by venogram, prior to implantation.  
The mean sheep EJV diameter is 12.0 mm and has a standard deviation of 1.4 mm [115]. 
Assuming the diameters of this vein have a normal distribution, 95.5% of these veins will be 
within two standard deviations of the mean, 9.2-14.8 mm. The smallest sheep EJV diameter, 
          
 , in which a valve can remain competent can be found by substituting    , which 
corresponds to a non-distensible vein, into Equation (15): 
          
         (23) 
Equation (20) regulates the largest sheep EJV diameter,           
 , a valve can be safely 
placed in.  
A single valve size which is capable of fitting into most sheep EJV diameters is desirable 
to reduce the number of stents to be acquired and valves to be manufactured. A valve which can 
fit in the highest percentage of sheep EJV diameters will have its minimum and maximum    be 
the same distance away from the mean: 
                 
            
         (24) 
Substituting Equations (20) and (23) into Equation (24) yields: 
                            
Solving for    : 
           
This suggests that a valve of the proposed design scaled to have an outer diameter of 10.4 
mm will fit the highest percentage of sheep EJV diameters. Equations (20) and (23) indicate that 
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a 10.4 mm valve would fit into sheep EJVs with diameters ranging from 9.4 to 14.6 mm which 
accounts for 94% of the expected vein diameters, assuming normality (see Figure 77). Equation 




Figure 77: Probability density, assuming normality, of the sheep jugular vein diameter. A 10.4 mm diameter 
valve would fit into diameters ranging from 9.4 to 14.6 mm, which covers 94% of the expected diameter sizes.  
 
Valve Sizing for Humans 
In humans, the Valsalva maneuver can be used to cause veins to distend, with greater 
dilation occurring when the individual is inclined in the reverse Trendelenburg position than in 
the supine position [151, 211, 212]. The diameter of a human vein in the 15% reverse 
Trendelenburg position during a Valsalva maneuver is assumed to be   , the fully distended 
diameter of the vein. The vein diameter may be visualized and measured by venogram or 
ultrasound. The methods used by Fronek are an example of using duplex ultrasound to take this 



















Sheep Jugular Vein Diameter (mm)
10.4 mm Valve
( 94%)
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Fronek measured the mean diameter of the CFV of individuals at rest in the supine 
position and during a Valsalva maneuver in the 15% reverse Trendelenburg position (  ) [151]. 
On the average,    was 21% larger than the diameter of the vein at rest and had a mean diameter 
of 14.27 mm with a standard deviation of 2.49 mm [151]. Hertzberg measured the popliteal vein 
of individuals at rest in the supine position to be 6.8 mm with a standard deviation of 2.11 mm 
[213]. Assuming that the diameter of the popliteal vein also distends from rest by 21% during a 
Valsalva maneuver in the 15% reverse Trendelenburg position, the popliteal vein’s mean    is 
8.2 mm. The standard deviation of    for the popliteal vein is assumed to remain the same as 
when resting, 2.11 mm. Assuming a normal distribution, 95.5% of the   s of the CFV and 
popliteal veins will be within two standard deviations of their means, 9.3-19.3 mm and 4.0-12.4 
mm respectively.  
The smallest vein diameter,           
 , in which a valve can remain competent can be 
found by substituting       , which corresponds to a 21% distention from rest, into Equation 
(15):   
          
         (25) 
Equations (25) and (20) can be used to find the    range for a stented valve of the 
proposed design of any scale for a human. From this information, a set of valve sizes can be 
specified which will fit into the CFV, femoral, and popliteal veins of the general population. As 
the femoral vein is typically smaller than the CFV and larger than the popliteal vein in an 
individual, it is assumed that a set of valves that fits at least 90% of the CFV and popliteal veins 
in the general population will also service the femoral veins encountered. 
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A proposed set of 5 valve sizes is shown in Table 18 which will cover 90-96% of the 
probable range of CFV and popliteal vein diameters of the general population. This set was 
developed by attempting to satisfy the following criteria: 
1) Service at least 90% of both the CFV and the popliteal veins to ensure adequate 
coverage of the general population. 
2) Offer continuous size coverage throughout the entire set to ensure that valves 
within the set will also fit the femoral veins of the general population. 
3) Each individual valve size is to service at least 15% of at least one vein type to 
warrant its production. 
4) Have the overlap of two valve    ranges occur in multiples of 0.5 mm to make it 
easier for a surgeon to discern which valve size to use.    
To simplify the selection process, each valve was named from the NATO phonetic 
alphabet, with Alpha corresponding to the smallest valve size and Echo the largest valve size 
(see Table 18). Assuming normality, the probability of each vein’s    occurring in the range of 
each valve was calculated using Minitab v 13.2 (Minitab, Inc, State College, PA) and is shown in 
Table 18, Figure 79, and Figure 78. The CFV will primarily be serviced by the largest three 
valves, and the popliteal by the smallest 3 valves (see Table 18, Figure 78 and Figure 79).   
A guide for surgeons to select the appropriately sized valve is shown in Table 19. In the 
event of a measurement for    being on the boundary of two valve sizes, it is recommended that 
the larger valve size be chosen to ensure the correct fixation and to keep the shear rates low. For 
example, it is recommended that a vein with a    of 14.5 mm have the Echo valve placed inside 
of it. The guide in Table 19 also displays the maximum expanded diameter of the stent to be 
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housed inside each valve, indicating the size of balloon for surgeons to use during insertion. 
These stent sizes were found using Equation (22). 
The flow rate through the popliteal vein is approximately 30% of that through the CFV 
[214]. While the valves best suited to fit inside the popliteal vein are much smaller than the one 
analyzed in the CFD simulation in Chapter 4, an elevated shear rate will likely not occur because 
of the lower flow rate.  
 







Max  Diameter* 
(mm) 
% of CFV 
diameters 
serviced 
% of Popliteal 
diameters 
serviced 
Alpha 5 5.5 7.0 0 18 
Bravo 6.4 7.0 9.0 2 36 
Charlie 8.2 9.0 11.5 12 30 
Delta 10.4 11.4 14.6 40 6 
Echo 13.2 14.5 18.5 42 0 
 Entire Set 5.5 18.5 96 90 
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Table 19: Sizing guide for the suggested valve set. 
Diameter* (mm) Valve Fully Expanded Stent Diameter (mm) 
5.5-7 Alpha 8 
7-9 Bravo 10 
9-11.5 Charlie 13 
11.5-14.5 Delta 17 
14.5-18.5 Echo 21 
*Diameter measured by ultrasound during a Valsalva maneuver in the 15% reverse 
Trendelenburg position. In the event of the diameter falling on the boundary of two valve sizes, 
the larger size should be selected.  
 
 
Figure 78: Probability density, assuming normality, of the CFV's fully distended diameter. The percent 
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Figure 79: Probability density, assuming normality, of the popliteal vein's fully distended diameter. The 
percent probability of a diameter falling in the range of selected valve sizes is indicated. 
 
Clinician Procedure 
A flow chart for the role of clinicians in implantation and evaluation of the proposed 
valve is shown in Figure 80. Clinicians will identify where valves should be implanted by 
identifying refluxing vein segments and then visualizing implantation sites using venogram or 
ultrasound. The diameter at the implantation site of each vein will be measured in the 15% 
reverse Trendelenburg position using venogram or ultrasound. Table 19 will be used to select the 
appropriate valve size to be implanted in each location. The valves may then be percutaneously 
delivered via catheter and the valve’s stents will then be expanded by balloon. Additional valves 
may be implanted in the same vein segment at least 13 cm apart at locations where Doppler 
ultrasound reveals reflux to exceed 3 mL/min when patients perform a Valsalva maneuver. After 
the procedure the primary endpoints will be assessed for each implanted valve, and the 
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• Identify refluxing vein segments 
• Visualize implantation sites (0.5-2cm blow 




• Measure vein diameter in the 15% reverse 
Trendelenburg position during a Valsalva 
maneuver using venogram or ultasound 
Select Valve 
Size 
• Use valve sizing guide to select the 
appropriately sized valve. 
Implant 
Valve 
• Percutaneously deliver valve via catheter. 
• Expand valve stent with balloon 
• Check for reflux using Doppler and implant 
additional valves as needed 
Assess 
Patient 
• Measure primary and secondary endpoints at 
8 weeks and 6, 12, and 18 months 
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CHAPTER 7: EVALUATION AND DISCUSSION 
Valve Design Evaluation 
The proposed valve met every design specification for an effective prosthetic venous 
valve. On the average, the valve allows less than 0.5 mL/min of reflux at low and high retrograde 
pressures even after 500,000 cycles, suggesting that it will reduce the reflux of individuals with 
venous reflux by more than 99.6% [32]. The valve closes in less than 0.07 seconds and allows 
the distal pressure to rise to an average of 7% of the equilibrium pressure 30 seconds after a 
simulated ankle flexion. The valve increases the outflow resistance an average of 2.3 
mmHg*min/L which is much less than venous obstructions which increase the outflow resistance 
by at least 5 mmHg*min/L [48]. The valve can fit in a 16 French catheter and is capable of 
percutaneous delivery. The base of the valve is 1.5 times the diameter of the vein it is to be 
implanted which will help it to be oriented correctly upon deployment.  
Thus far the valve has demonstrated that it has low thrombogenicity. The maximum shear 
rate in the valve after a Valsalva maneuver is approximately 2300 s
-1
, which puts it at low risk 
for shear induced thrombosis. Fluid behind the valve’s leaflets is ejected with a forward flow rate 
of 400 mL/min, suggesting that thrombus formation will not occur at this location when an 
individual is at rest in the supine position. The material of the valve, PVA, has passed the ISO 
and USFDA biocompatibility tests and has been shown to be less thrombogenic than Dacron in 
previous testing [144, 165, 175]. PVA is also capable of drug delivery and can elute anti-
coagulation drugs, such as citrate [145]. A stented valve remained patent in a porcine blood flow 
loop for 3 hours, demonstrating that its short term patency is at least equivalent to the Midha 
valve which had previously held the record for the longest occlusion time in such a loop. 
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 Valves of the proposed design can function and expand into veins with fully distended 
diameters that are 1.1-1.4 times the valve’s initial diameter. With this versatility, a 10.4 mm 
valve is expected to fit in 94% of sheep EJVs, and a set of 5 valves is expected to fit in 90-96% 
of the CFV, femoral, and popliteal veins.  
While many prosthetic venous valves have been developed, only a handful have reported 
experimental testing results. While the experimental methods for testing these valves has 
differed, an attempt has been made to briefly compare their performances (see Table 20) [102, 
123, 132, 137, 140, 142, 143, 145]. Only three valves, the Sathe valve, Moriyama valve, and the 
valve presented in this work, have demonstrated their ability to reduce reflux below 3 mL/min 
(see Figure 81); however, only the present valve did not increase the outflow resistance to 
venous obstruction levels [142, 143]. While the maximum shear rate during forward flow has not 
been calculated for most valves, shear induced platelet aggregation is expected to be a common 
failure mode for many previously developed prosthetic venous valves due to their relatively 
small orifices or sharp changes in geometry.  
As the prosthetic venous valve presented in this work is the only valve to meet every 
design specification for an effective prosthetic venous valve, this valve shows the most potential 
to be a minimally invasive treatment for deep venous reflux.  
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Table 20: Performance comparison of prosthetic venous valves which underwent experimental testing (data extracted from [102, 122, 123, 132, 137, 140, 
142, 143, 145]). The valve presented in this work is referred to as "Tanner".  
    





bPVV oPVV Liu Sathe Midha
Reflux rate (mL/min) ≤ 8 0.3-0.4 145 40-120 87.5 14.25 2.04 30.8 12-16 < 0.3 30.8
Reflux rate after fatigue 
(mL/min)
≤ 8 < 0.1 - - - - - - - < 0.3 41.1
Leaflet closing time (s) < 0.5
0.067
- 0.43-0.49 1.38** - - - - - -
Distal pressure rise 30 
seconds after a simulated 
calf flexion (%)
≤  10 7 - - - - ~10 100 - - -
Increased outflow 
resistance by the valve 
(mmHg*min/L)
< 5 2.3 333* 322* 1.37-2.33 1.15-4.66 > 372 > 46 - 324.6 7.3
Fluid behind leaflets washes 
out under forward flow
Yes Yes - - - - Yes*** No*** - - Yes***
Smallest diameter valve can 
be placed in without 
buckling (mm)
≤ 8.5 6.5 - - - - - - - - 10




< 3500 2300 - - 7600 - - - - > 10E3 3000
Time to occlusion when 
running heparinized (3.5 
mL/L) porcine blood in a 
flow loop (Hours)
> 3 > 3 - - - - - - - 0.3 > 3
*Resistance of the testing system not reported so the total resistance of the valve and the testing system are presented.
**Only the results for a 2:1 scale mockup of the prototype valve were reported
***Applied flow rate was higher than 400 mL/min
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Figure 81: Comparison of reflux flow rate of prosthetic venous valves which underwent experimental testing 
(data extracted from [102, 122, 123, 132, 137, 140, 142, 143, 145]). The valve presented in this work is referred 
to as "Tanner". 
 
Main Contributions: 
The present work made novel contributions in the field of prosthetic venous valve 
development in the areas of valve design, design specifications, verification testing, 
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Valve Design 
Novel features of the valve include the slits in the leaflet corners to improve sealing and 
the shape of the leaflets to help prevent prolapse. The transition of the valve orifice from being 
elliptical to lemon shaped from the shoulder to half the height of the leaflets, which helps to 
prevent leaflet prolapse, and then remaining lemon shaped, which promotes sealing, is also 
unique. The design of a valve which can expand from its initial diameter by more than 40% is 
also original.  
Design Specifications and Verification Testing 
Previous design specifications for reflux have been based on the volume ejected from the 
calf muscle pump or the amount of flow through the femoral vein when at rest in the supine 
position [143, 145]. However, the specification for competency in this work was made relative to 
the amount of reflux seen in individuals with venous reflux, ensuring that a prosthetic valve that 
meets this specification will reduce the amount of reflux below the level that will contribute to 
CVI symptoms. Measuring the reflux by weight, which increased the precision of the test, was 
unique to this work. Additionally, specifications for the diameter of a constricted vein in which a 
valve is to remain competent and not buckle have not heretofore been proposed or verified in 
testing.   
A specification for the closing time of a prosthetic valve is unique to this work as well as 
measuring the closing time using a visual recording. While previous researchers have recorded 
the rise in distal pressure after a simulated calf flexion, a definitive design specification has not 
previously been proposed for this test [142]. A design specification for outflow resistance, which 
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ensured that the valve did not impede flow to the level of venous obstruction, had not been 
previously proposed.  
A similar washout test was performed for the Midha valve which applied a 75mmgHg 
pressure head using water [145]. The resulting forward flow rate in Midha’s washout test was 
approximately 2700 mL/min, which is higher than the maximum flow of 1600 mL/min seen in 
the femoral vein, which biased the test towards washing out [137, 145, 151]. The washout test in 
the present work used a forward flow rate of 400 mL/min, corresponding to the flow rate of a 
subject in the supine position, being the situation where the valve is most likely to develop 
stagnant flow. Additionally, a glycerol solution with a similar viscosity as blood was used as the 
working fluid, further making the washout test in the present work more indicative of flow 
behind the valve's leaflets in a human vein.  
A stented prosthetic venous valve had not been placed in a porcine blood flow loop 
before. A mathematical model to estimate the minimum catheter size in which a prosthetic 
venous valve can fit had not been previously proposed. 
Computational Analysis 
To date, this is the first work to use a finite element simulation to analyze a prosthetic 
venous valve. The material properties of 20 wt% PVA undergoing 4 freeze-thaw cycles at a slow 
thawing rate used in the finite element simulation had not been previously estimated. 
While other CFD simulations of prosthetic valves inside the femoral vein have been 
performed, this was the first to use the deformed geometry of the valve when expanded by a stent 
in the vein (see Figure 47), the physiologic maximum flow rate of 1600 mL/min, or a fully 
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developed flow profile at the inlet to decrease the computational burden of the model [137, 139, 
145].  
Valve Placement 
A method to determine the minimum distance between implanted valves in the same 
venous segment has not heretofore been set forth for any prosthetic venous valve. This work is 
the first to propose a method to determine the diameters in which a valve can be placed and 
maintain full functionality. The suggestion of a set of vein valve sizes which could service the 
CFV, femoral, and popliteal veins is also a novel contribution, as well as the creation of a guide 
for surgeons to select the correct valve size.  
Future Work 
Additional fatigue testing of the proposed valve should be performed to determine if the 
valve will fail from fatigue before 9 million cycles, the expected number of cycles the valve will 
undergo in its lifetime, at a frequency of 0.67 Hz [143].  
After stents of the appropriate size are obtained the animal study can be performed. If 
animal testing indicates that the valve will be successful in human testing, an IRB protocol to test 
the valve in humans should be prepared. After IRB approval, the proposed human study could 
then be performed. 
While a set of valves for the CFV, femoral, and popliteal veins was proposed, a set of 
valves which can service the superficial and perforating veins could be developed which would 
allow the valve to treat multisystem reflux. Human testing using the valve to correct multisystem 
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reflux could then be pursued. A stented valve also has the potential to treat outflow obstruction 
in addition to venous reflux in subjects, which could be researched further.  
While the shoulder of the proposed valve provided a visual cue to align a stent inside the 
valve correctly during manufacturing, it did not act as a ledge to stop the stent from protruding 
into the leaflets. Another method to help align the stent during manufacturing could likely be 
found, and the shoulder should be removed. The removal of the shoulder would reduce the bulk 
of the valve and potentially allow the valve to fit into a smaller catheter size. However, the 
removal of the shoulder will likely change the smallest diameter in which the valve can remain 
competent and this verification test would need to be performed again.    
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